Brii Biosciences
Breakthrough innovation & insight

Brii Biosciences Limited
腾盛博药生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

Stock Code: 2137

2026
Interim Report

CONTENTS

CORPORATE PROFILE

Brii Biosciences Limited is a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet medical need. In the first six months of 2026, the Company generated additional clinical data supporting its differentiated HBV functional cure strategy, while continuing to progress its internally discovered early-stage therapeutic candidates, supported by its RNA-based technology platforms and integrated research and development capabilities in China and the United States.

The Company advanced its differentiated HBV functional cure portfolio through a combination-based strategy built around BRII-179 and elebsiran, supported by three ongoing Phase 2b studies, namely ENSURE, ENRICH and ENHANCE studies. End-of-study data from the Phase 2b ENSURE study and topline end-of-treatment data from the Phase 2b ENRICH and ENHANCE studies expanded the clinical evidence supporting the Company's differentiated combination approach and the potential role of BRII-179 in improving functional cure outcomes. Findings from these studies have informed the potential design of a Phase 3 registrational study, with longer-term follow-up ongoing and more complete data expected in the second half of 2026.

Beyond HBV, the Company continued to invest in its internal discovery capabilities and the RNA-based technology platforms. Subsequent to the Reporting Period, in August 2026, the first participant was dosed in a clinical study evaluating BRII-5395, an internally developed mRNA therapeutic vaccine for advanced hepatocellular carcinoma. This milestone marked the first clinical evaluation of an RNA-based therapeutic originating from the Company's internal discovery efforts. During the first half of 2026, the Company progressed multiple internally discovered candidates across various stages of discovery and preclinical development, including programs that extend the application of our technology platforms into additional therapeutic areas beyond infectious diseases.

The Company is actively seeking external partnership opportunities to optimize internal resource allocation and maximize the development and commercialization potential of non-core pipeline assets.

Looking ahead, the Company remains focused on advancing its differentiated HBV portfolio and RNA-based technology platforms, with the aim of building a diversified pipeline and delivering sustainable innovation for patients with unmet clinical needs.

CORPORATE INFORMATION

BOARD OF DIRECTORS

Executive Directors

Dr. Zhi HONG *(Chairman and Chief Executive Officer)*
Dr. Ankang LI

Independent non-executive Directors

Mr. Gregg Huber ALTON
Dr. Martin J MURPHY JR
Ms. Grace Hui TANG
Mr. Yiu Wa Alec TSUI
Dr. Taiyin YANG

AUDIT AND RISK COMMITTEE

Ms. Grace Hui TANG *(Co-Chairlady)*
Dr. Taiyin YANG *(Co-Chairlady)*
Mr. Yiu Wa Alec TSUI

REMUNERATION COMMITTEE

Dr. Martin J MURPHY JR *(Chairman)*
Ms. Grace Hui TANG
Mr. Yiu Wa Alec TSUI

NOMINATION COMMITTEE

Mr. Gregg Huber ALTON *(Chairman)*
Dr. Zhi HONG
Dr. Martin J MURPHY JR
Ms. Grace Hui TANG

STRATEGY COMMITTEE

Dr. Ankang LI *(Chairman)*
Mr. Gregg Huber ALTON
Dr. Taiyin YANG

JOINT COMPANY SECRETARIES

Ms. Wing Tsz Wendy HO
Dr. Ankang LI

AUTHORISED REPRESENTATIVES

(for the purpose of the Listing Rules)
Dr. Ankang LI
Ms. Wing Tsz Wendy HO

LEGAL ADVISERS

As to Hong Kong laws:
Edwin Kwok & Co

As to PRC laws:
Global Law Office, Shanghai

As to Cayman Islands law:
Maples and Calder (Hong Kong) LLP

AUDITOR

Deloitte Touche Tohmatsu
Registered Public Interest Entity Auditor

COMPLIANCE ADVISOR

Somerley Capital Limited

REGISTERED OFFICE

PO Box 309, Ugland House
Grand Cayman KY1-1104
Cayman Islands

CORPORATE INFORMATION

CORPORATE HEADQUARTERS

3rd Floor, Building 7
Zhongguancun Dongsheng
International Science Park
No. 1 North Yongtaizhuang Road
Haidian District, Beijing 100192
China

WeWork One City Center
Suite 05-110, 110 N Corcoran St
Durham, NC 27701
United States of America

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1920, 19/F
Lee Garden One
33 Hysan Avenue
Causeway Bay, Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Maples Fund Services (Cayman) Limited
PO Box 1093, Boundary Hall
Cricket Square
Grand Cayman KY1-1102
Cayman Islands

HONG KONG SHARE REGISTRAR

17/F, Far East Finance Centre
16 Harcourt Road
Hong Kong

PRINCIPAL BANKERS

Bank of Beijing
Bank of China (Hong Kong)
China Merchants Bank
First Citizens Bank
Goldman Sachs International Bank
J.P. Morgan Chase Bank

COMPANY WEBSITE

www.briibio.com

STOCK CODE

2137

LISTING DATE

July 13, 2021

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

Brii Bio is a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet medical need. Our pipeline combines a differentiated HBV functional cure portfolio with internally discovered early-stage therapeutic candidates, supported by our RNA-based technology platforms and integrated research and development capabilities in China and the United States.

In the first half of 2026, we continued to advance our HBV functional cure strategy. We presented end-of-study data from our Phase 2b ENSURE study and subsequently announced topline data from Phase 2b ENRICH study and ENHANCE study, further expanding the clinical evidence supporting our differentiated combination approach and the potential role of BRII-179 in improving functional cure outcomes.

Beyond HBV, we continued to advance our internal discovery capabilities and invest in the development of our RNA-based technology platforms.

Subsequent to the Reporting Period, the first participant was dosed in a clinical study evaluating BRII-5395, an internally discovered mRNA therapeutic vaccine for advanced hepatocellular carcinoma (HCC). This milestone represents the first clinical evaluation of an RNA-based therapeutic originating from Brii Bio's internal discovery efforts. While BRII-5395 is an mRNA therapeutic vaccine, the Company's broader RNA platforms encompass multiple RNA modalities. During the first half of 2026, Brii Bio progressed multiple internally discovered candidates across various stages of discovery and preclinical development, including programs that extend the application of our technology platforms into additional therapeutic areas beyond infectious diseases.

Our discovery activities are supported by our research and translational capabilities in China and the United States, as well as external collaborations that complement our internal discovery efforts. Together, they fuel the continued advancement of our RNA-based technology platforms and broader discovery initiatives.

Looking ahead, we will remain focused on advancing our strategic priorities across our HBV portfolio and the broader discovery pipeline. By leveraging our integrated global R&D capabilities, clinical development expertise and expanding technology platforms, we are building a diversified pipeline and driving sustainable long-term innovation.

MANAGEMENT DISCUSSION AND ANALYSIS

Pipeline Summary

We have developed an extensive pipeline targeting diseases with significant unmet medical need. Our lead programs are centered on HBV functional cure, primarily in China, the world's largest HBV market.

The table below outlines the status of our key product candidates as of the date of this report:

Indication	Program	Modality	Preclinical	Phase 1	Phase 2	Phase 3	Brii Rights	Partner
HBV Cure	BRII-179	Therapeutic Vaccine					Worldwide	
	Elebsiran	siRNA					Greater China(1)	Vir Biotechnology
HDV	Elebsiran + Tobevibart	siRNA + mAb					Greater China(2)	Vir Biotechnology
HBV+ HCC	BRII-5395	mRNA					Worldwide	
MDR	Soralimixin	Cyclic Peptides					Ex-China(3)	健康元 Joincare
HIV	BRII-732	Long-acting oral					Worldwide	
	BRII-753	Long-acting injectable					Worldwide	

(1) Brii Bio obtained exclusive license from Vir Biotechnology for the research, development, and commercialization of elebsiran and tobevibart in the Greater China. Greater China includes Mainland China, Macau, Hong Kong and Taiwan.

(2) Our collaborator, Vir Biotechnology, is currently conducting Phase 3 studies of elebsiran and tobevibart for the treatment of HDV infection.

(3) Joincare Group has obtained an exclusive license from Brii Bio for the research, development, and commercialization of soralimixin in the Greater China. Brii Bio retains the rights to soralimixin outside the Greater China.

BUSINESS REVIEW

During and immediately subsequent to the Reporting Period, the Company made progress across its HBV portfolio and internally discovered pipeline.

In HBV, data from the Phase 2b ENSURE, ENRICH and ENHANCE studies expanded the clinical evidence supporting the Company's differentiated functional cure strategy and informed the potential of BRII-179 as part of combination regimens.

In discovery, the Company continued to strengthen its internal discovery capabilities and develop its RNA-based technology platforms. Multiple internally discovered candidates, including BRII-5395, progressed across various stages of discovery and preclinical development toward clinical evaluation. These programs are supported by the Company's research capabilities, including its integrated lab operations in China and AI-enabled collaboration with OpenBench.

Operationally, the Company remained focused on disciplined resource allocation and development efficiency. As of June 30, 2026, the Company maintained a robust cash position, which is expected to fund the planned development of its clinical-stage programs, RNA-based technology platforms and broader discovery pipeline through 2029.

The Company's key achievements as of the date of this report, along with planned next steps and anticipated milestones, are set out below.

Core Clinical Pipeline Highlights and Upcoming Milestones

HBV Program

The Company has generated a growing body of clinical evidence across its HBV functional cure portfolio through the completed Phase 2b ENSURE study and the ongoing Phase 2b ENRICH and ENHANCE studies. These studies evaluate differentiated combination approaches involving the Company's HBV therapeutic candidates, including BRII-179, a recombinant protein-based HBV immunotherapeutic, and elebsiran, an HBV-targeting siRNA.

BRII-179-related studies and plans

BRII-179 is a novel recombinant protein-based HBV immunotherapeutic candidate that expresses the Pre-S1, Pre-S2 and S HBV surface antigens and is designed to induce enhanced B-cell and T-cell immune responses. The Company holds exclusive global rights to develop and commercialize BRII-179.

BRII-179 has been evaluated across the Phase 2b ENSURE, ENRICH and ENHANCE studies to further define its potential role in HBV functional cure combination regimens.

The Phase 2b ENSURE study was designed to assess the efficacy and safety of combination approaches aimed at improving functional cure outcomes. Cohorts 1-3 evaluated elebsiran in combination with PEG-IFNα compared to PEG-IFNα monotherapy, while Cohort 4 evaluated the potential role of BRII-179 in enhancing immune responsiveness and improving HBsAg loss rates.

In May 2026, the Company presented end-of-study data from Cohorts 1-4 of the ENSURE study at EASL Congress 2026. The results demonstrated that:

- The HBsAg loss benefit observed in the elebsiran and PEG-IFNα combination cohorts resulted in a higher functional cure rate compared with the PEG-IFNα-alone cohort.
- BRII-179-experienced participants achieved higher functional cure rates, particularly among anti-HBs responders, supporting the potential role of BRII-179 in achieving durable immunological control of HBV.

The Phase 2b ENRICH and ENHANCE studies were designed to further evaluate the role of BRII-179 in combination regimens for HBV functional cure. Patient treatment in both studies has been completed.

The ENRICH study evaluated BRII-179 as a priming therapy administered prior to treatment with elebsiran and PEG-IFNα. Topline end-of-treatment data from this study were announced in July 2026.

- At EOT, HBsAg loss rates were 42.9% (42/98) and 40.0% (20/50) across two BRII-179 dosing schedules (five doses administered once every three weeks and seven doses administered once every two weeks, respectively). These results were consistent with the HBsAg loss rate observed in ENSURE Cohort 4 of 41.9% (13/31) among patients previously treated with BRII-179, supporting the potential immune-priming role of BRII-179.
- Subgroup analyses from the ENRICH study suggest potential differentiation among participants with higher baseline HBsAg levels (1000-3000 IU/mL), consistent with prior findings from ENSURE Cohort 4, indicating that BRII-179 may induce beneficial immune responses across a range of baseline HBsAg levels in this difficult-to-treat population.

MANAGEMENT DISCUSSION AND ANALYSIS

The ENHANCE (Part A-1) study evaluated a concurrent triple combination of BRII-179, elebsiran and PEG-IFNα. ENHANCE (Part A-2) evaluated a sequential approach designed to potentially shorten PEG-IFNα therapy, with BRII-179 plus elebsiran administered during the first 24 weeks followed by 24 weeks of elebsiran and PEG-IFNα. Topline end-of-treatment data from this Phase 2b study were announced in July 2026.

- At EOT, the ENHANCE (Part A-1) study did not demonstrate improved HBsAg loss rates compared with ENSURE Cohorts 2 and 3, 29.7% (11/37), with an observed rate of 25.5% (25/98). Higher HBsAg loss rates, however, were observed compared with the PEG-IFNα control arm, 10.2% (5/49).

- In the ENHANCE study (Part A-2), the HBsAg loss rate at EOT was 22.5% (18/80), suggesting that a full course of PEG-IFNα therapy may be important for achieving optimal functional cure outcomes.

No new safety concerns have been identified across ENSURE, ENRICH and ENHANCE to date.

The Company plans to present detailed data from the ENRICH and ENHANCE studies, including additional efficacy, safety, subgroup analyses and available follow-up data, at a scientific conference in the second half of 2026.

Following the product recall involving a commercial assay kit used for HBsAg testing in the ENHANCE study disclosed in the Company's announcement dated August 21, 2026, the Company has completed the retesting of the potentially affected samples. Based on the retesting results, the Company confirmed that the matter did not affect the announced EOT HBsAg data for Part A-2 of the ENHANCE study and its overall interpretation of the study results.

Elebsiran and Tobevibart related studies and plans

Elebsiran is an investigational hepatitis B virus-targeting siRNA discovered by Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicate that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with HBV and chronic hepatitis delta. We in-licensed exclusive rights to develop and commercialize elebsiran for the Greater China territory from Vir Biotechnology in 2020.

Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the HBsAg. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor's Xtend™ technology to extend half-life. Tobevibart is administered subcutaneously, and is currently in clinical development for the treatment of patients with chronic hepatitis delta. We in-licensed exclusive rights to develop and commercialize tobevibart for the Greater China territory from Vir Biotechnology in 2022.

- Vir Biotechnology continues to evaluate elebsiran in combination with tobevibart for the treatment of chronic hepatitis delta (CHD) in its ECLIPSE registrational program. ECLIPSE 1 and ECLIPSE 3 are fully enrolled, with topline data from ECLIPSE 1 expected in the fourth quarter of 2026 and topline data from ECLIPSE 2 and ECLIPSE 3 expected in the first quarter of 2027.

Discovery and Early Development Program Highlights and Upcoming Milestones

During the Reporting Period, the Company expanded its discovery and early development activities beyond infectious diseases into new therapeutic areas, advancing multiple internally generated programs across various stages of discovery and preclinical development, with a focus on generating differentiated therapeutic opportunities in diseases with significant unmet medical needs. The Company continues to advance its RNA-based technology platforms to support the development of new therapeutic candidates across a broader range of disease areas.

The Company's discovery work is underpinned by an integrated global R&D organization spanning China and the United States. In China, the Company operates a translational research laboratory in Beijing and a fully integrated discovery laboratory in Shanghai, with internal capabilities across cell and molecular biology, medicinal chemistry, ADME/DMPK, toxicology and CMC, complemented by the Company's U.S.-based discovery team and external collaborations.

BRII-5395 is a novel mRNA therapeutic vaccine internally developed by Brii Bio. It is being evaluated as part of a combination immunotherapy approach for HBV-related hepatocellular carcinoma (HCC).

- On August 12, 2026, subsequent to the Reporting Period, the first participant was dosed in a clinical study evaluating BRII-5395 in participants with advanced HCC. The study, conducted at the Cancer Hospital of the Chinese Academy of Medical Sciences, is designed to evaluate the safety, tolerability, immunogenicity and preliminary anti-tumor activity of BRII-5395 in combination with an anti-PD-1 antibody and an anti-VEGF antibody. Many patients with advanced HCC derive limited benefit from current immune checkpoint inhibitor-based regimens.

- As the first internally developed RNA-based cancer therapeutic vaccine to enter clinical evaluation, BRII-5395 represents an important milestone in the advancement of the Company's internal discovery capabilities and RNA-based technology platforms.

While BRII-5395 is an mRNA therapeutic vaccine, the Company's broader RNA platforms encompass multiple RNA modalities. In addition, the Company has extended the application of its technology platforms into additional therapeutic areas beyond infectious diseases.

Further updates on the Company's RNA technology platforms and broader discovery programs are expected throughout the remainder of 2026. The Company is actively exploring partnership opportunities to advance selected discovery programs to maximize the value of its emerging pipeline.

Additional Clinical Programs

Multi-drug Resistant Gram-Negative Bacteria Infections Program

Soralimixin (formerly known as BRII-693) is a novel cyclic peptide in development for the treatment of MDR gram-negative bacterial infections. Based on a combination of increased in vitro and in vivo potency and an improved safety profile compared with currently available polymyxins, soralimixin has the potential to be an important addition to the arsenal of hospital-administered intravenous antibiotics for the treatment of critically ill patients with gram-negative bacterial infections. Soralimixin has a highly differentiated safety and efficacy profile to address the most difficult-to-treat infections due to Acinetobacter baumannii and Pseudomonas aeruginosa, including infections due to MDR isolates resistant to carbapenem antibiotics.

The Company's collaborator, Joincare Group, is advancing the development and commercialization of soralimixin in Greater China under an out-licensing agreement entered into in July 2025. The Company retains all rights outside Greater China and continues to seek partnership opportunities for those rights.

- In June 2026, Joincare Group completed the first subject dosing for Phase I study of soralimixin in China for the treatment of multidrug-resistant Gram-negative bacterial infections.
- The U.S. FDA has granted soralimixin a Qualified Infectious Disease Product designation, which offers various incentives for its development in the U.S., including priority review and eligibility for the U.S. FDA's Fast Track Designation. This designation also opens the possibility for extended regulatory and market exclusivity in the U.S.

HIV Infection Program

The Company is actively seeking strategic partnerships for long-acting HIV therapeutic candidates to maximize the development and commercialization potential, including:

- **BRII-753** is an NRTTI, which is an internally discovered NCE prodrug of EFdA currently in pre-clinical development. It is being developed as a long-acting subcutaneous injection with the potential to be given once monthly, once quarterly or twice yearly. It can be used as a combination therapy for HIV treatment and as monotherapy for pre-exposure prophylaxis.
- **BRII-732** is a proprietary NCE prodrug that, upon oral administration, is rapidly metabolized into EFdA and is under evaluation as a potential HIV treatment or prevention option. EFdA is an NRTTI, acting as both a chain terminator and translocation inhibitor of HIV. BRII-732 has completed Phase 1 studies with the potential for development as part of an oral, once-weekly, long-acting combination treatment option for HIV patients.

WE MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET ANY OF THE ABOVE PRE-CLINICAL STAGE OR CLINICAL STAGE DRUG CANDIDATES SUCCESSFULLY.

Other Corporate Updates

On April 16, 2026, the Company and Brii Biosciences Offshore Limited, a subsidiary of the Company, submitted a Demand for Arbitration against Vir Biotechnology, Inc. (the "**Arbitration**").

The Company announced the commencement of the Arbitration on April 16, 2026 and provided a further update on May 22, 2026. As of June 30, 2026, the Arbitration remained in its early stages, and the parties had not reached a resolution of the claims.

In June 2026, the Company announced the approval of a HK$60 million share buyback program to buy back Shares not exceeding 10% of the total number of issued Shares (excluding treasury shares (as defined under the Listing Rules)) as of June 16, 2026, underscoring the Company's confidence in its prospects.

Research and Development

We are a biotech company primarily engaged in pharmaceutical R&D activities. We recognize that R&D is fundamental for shaping our therapeutic strategy and sustaining our competitiveness in the biopharmaceutical industry. We prioritize diseases based on patients' needs, aiming to provide viable solutions to diseases with significant unmet medical need.

Our R&D capabilities, both in-house and through collaborations, enable us to identify and innovate therapies for both the Chinese and international markets. Led by industry veterans, our in-house R&D team is supported by a strong scientific advisory board and strategic partnerships with global pharmaceutical and biotech companies, along with contract research organizations, contract manufacturing organizations, contract development and manufacturing organizations, and research institutions. With our competitive advantage in cross-border and organic operations, we plan to further enhance our capacity and capabilities.

Our R&D executive team includes Chief Executive Officer Dr. Zhi Hong, Chief Medical Officer Dr. David Margolis, Chief Scientific Officer Dr. Brian A. Johns, Chief Technology Officer Dr. Ellee de Groot, Head of Preclinical Sciences and Translational Research Dr. Qing Zhu and Head of China Clinical Development Mr. Haifeng Cao. Our esteemed Board and scientific advisory board members, who possess diverse industry expertise and a proven record in successful drug development, direct our R&D processes and candidate selection through their extensive knowledge across various disciplines.

Our multi-pronged R&D strategies are designed with flexibility in mind, resulting in expenses that vary according to the number and scale of projects each year. Our R&D expenses for the period ended June 30, 2026 amounted to RMB98.3 million. We remain committed to leveraging our technology and R&D capabilities to broaden our life sciences research and application capabilities and product candidate portfolio.

MANAGEMENT DISCUSSION AND ANALYSIS

Commercialization

Our pipeline includes therapeutic candidates, encompassing both programs with global rights and with in-licensed Greater China rights.

As of the date of this report, our efforts have primarily focused on developing our therapeutic candidate pipeline. Most of our programs are in various stages of clinical development, and we do not anticipate sales or commercialization of drug candidates in the immediate future. As our pipeline gradually matures, we will evaluate strategic commercialization options, ensuring that we maximize their potential in addressing critical unmet medical needs.

FUTURE DEVELOPMENT

The Company will continue to develop therapies that improve patient health and expand treatment options in diseases with high unmet medical need by leveraging its internal discovery capabilities, RNA-based technology platforms and selective external partnerships.

Data generated from the ENSURE, ENRICH and ENHANCE studies have informed the potential design of a Phase 3 registrational study, with results observed to date indicating that the ENRICH-like study design may provide the preferred basis for further development. Longer-term follow-up remains ongoing, and more complete data are expected to be presented in the second half of 2026. However, in light of the ongoing Arbitration, the Company cannot commit to or invest in a Phase 3 study of an elebsiran-containing combination therapy unless and until the claims in the arbitration are satisfactorily resolved. The Company will evaluate the appropriate development path based on the complete clinical data and developments in the Arbitration.

We will continue to invest in the development of RNA-based technology platforms encompassing multiple RNA modalities to address novel therapeutic targets. For our other programs, we are seeking partnerships for continued development, allowing us to optimize our resources while maximizing the development and commercialization potential.

Our long-term strategy focuses on expanding our pipeline through in-house discovery and strategic licensing opportunities. We aim to explore business development opportunities, especially those involving the out-licensing of our internally discovered therapeutic candidates for international markets. To ensure sustainable development, we will continue to optimize our organization to foster innovation and enhance our business development efforts to develop therapies to improve patient outcomes across diseases with high unmet medical need.

SUBSEQUENT EVENTS

Save as disclosed in this report, the Directors are not aware of any significant event requiring disclosure that has taken place subsequent to June 30, 2026, and up to the date of this report.

FINANCIAL REVIEW

1. Other income

	Six months ended June 30,	
	2026	2025
	RMB'000	RMB'000
Bank interest income	19,216	27,134
Others	305	296
Government grants	–	697
Total	19,521	28,127

Our other income decreased by RMB8.6 million from RMB28.1 million for the six months ended June 30, 2025 to RMB19.5 million for the six months ended June 30, 2026. This was mainly due to the decrease in bank interest income of RMB7.9 million attributable to the declining interest rates on time deposits.

2. Other gains and losses

Our other gains and losses increased by RMB30.3 million from gains of RMB0.2 million for the six months ended June 30, 2025 to gains of RMB30.5 million for the six months ended June 30, 2026. The increase was primarily attributable to the changes in fair value in equity investments.

3. Research and development expenses

	Six months ended June 30,	
	2026	2025
	RMB'000	RMB'000
Third-party contracting cost	59,982	65,708
Employee cost	36,838	49,876
Amortization and depreciation	548	340
Others	964	1,096
Total	98,332	117,020

Our research and development expenses decreased by RMB18.7 million from RMB117.0 million for the six months ended June 30, 2025 to RMB98.3 million for the six months ended June 30, 2026. The decrease was primarily attributable to the decrease in employee cost of RMB13.1 million from RMB49.9 million for the six months ended June 30, 2025 to RMB36.8 million for the six months ended June 30, 2026, as a result of organizational optimization and adjustments to the compensation framework. The decrease was also attributable to the decrease in third-party contracting cost of RMB5.7 million from RMB65.7 million for the six months ended June 30, 2025 to RMB60.0 million for the six months ended June 30, 2026, mainly as the phase 2 study activities for the HBV programs wound down, partially offset by increased investment in early-stage discovery efforts during the Reporting Period.

4. Administrative expenses

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Employee cost	25,697	33,821
Professional fees	15,144	13,355
Depreciation and amortization	3,324	2,415
Office expenses	1,291	1,507
Others	7,120	7,127
Total	52,576	58,225

Our administrative expenses decreased by RMB5.6 million from RMB58.2 million for the six months ended June 30, 2025 to RMB52.6 million for the six months ended June 30, 2026. This was primarily attributable to the decrease in employee cost of RMB8.1 million from RMB33.8 million for the six months ended June 30, 2025 to RMB25.7 million for the six months ended June 30, 2026. The decrease was mainly resulting from organizational optimization and adjustments to the senior management compensation framework, partially offset by the increase in professional fees of RMB1.8 million and the depreciation and amortization cost of RMB0.9 million during the Reporting Period.

5. Liquidity and Capital resources

As at June 30, 2026, our bank and cash balances, including restricted bank deposits and time deposits, decreased to RMB1,770.8 million from RMB1,941.0 million as of December 31, 2025. The decrease is primarily due to payout of research and development activities and daily operations.

6. Non-IFRS measures

To supplement the Group's consolidated financial statements, which are presented in accordance with the IFRS, we also use adjusted loss for the period and other adjusted figures as additional financial measures, which are not required by, or presented in accordance with, the IFRS. We believe that these adjusted measures provide useful information to shareholders and potential investors in understanding and evaluating our consolidated results of operations in the same manner as they help our management.

Adjusted loss for the period represents the loss for the period excluding the effect of certain non-cash items and one-time events, namely share-based compensation expenses. The term adjusted loss for the period is not defined under the IFRS. The use of this non-IFRS measure has limitations as an analytical tool, and you should not consider it in isolation from, or as substitute for analysis of, our results of operations or financial condition as reported under IFRS. The presentation of such adjusted figures may not be comparable to a similarly titled measure presented by other companies. However, we believe that this and other non-IFRS measures are reflections of our normal operating results by eliminating potential impacts of items that the management do not consider to be indicative of our operating performance, and thus facilitate comparisons of operating performance from period-to-period and company-to-company to the extent applicable.

The table below sets forth a reconciliation of the loss to adjusted loss during the periods indicated:

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Loss for the period	(100,980)	(148,848)
Added:		
Share-based compensation	4,916	2,261
Adjusted loss for the period	(96,064)	(146,587)

The table below sets forth a reconciliation of the research and development expenses to adjusted research and development expenses during the periods indicated:

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Research and development expenses for the period	(98,332)	(117,020)
Added:		
Share-based compensation	2,396	1,692
Adjusted research and development expenses for the period	(95,936)	(115,328)

The table below sets forth a reconciliation of the administrative expenses to adjusted administrative expenses during the periods indicated:

	Six months ended June 30,	
	2026 RMB'000	2025 RMB'000
Administrative expenses for the period	(52,576)	(58,225)
Added:		
Share-based compensation	2,520	569
Adjusted administrative expenses for the period	(50,056)	(57,656)

7. Key financial ratios

The following table sets forth the key financial ratios for the dates indicated:

	As at June 30, 2026	As at December 31, 2025
Current ratio(1)	5,224%	6,073%
Gearing ratio(2)	NM	NM

(1) Current ratio is calculated using current assets divided by current liabilities as of the same date. Current ratio decreased mainly due to the decrease in bank and cash balances due to the payout of research and development activities and daily operations.

(2) Gearing ratio is calculated using interest-bearing borrowings less cash and cash equivalents divided by (deficiency of) total equity and multiplied by 100%. Gearing ratio is not meaningful as our interest-bearing borrowings less cash equivalents was negative.

8. Indebtedness

Borrowings

As at June 30, 2026, Group did not have any unutilized bank facilities, material mortgages, charges, debentures, loan capital, debt securities, loans, bank overdrafts or other similar indebtedness, hire purchase commitments, liabilities under acceptances (other than normal trade bills) or acceptance credits, which are either guaranteed, unguaranteed, secured or unsecured as of the date of this report.

Contingent Liabilities

As at June 30, 2026, the Group did not have any contingent liabilities.

Lease liabilities

We lease our office places under operating lease arrangements. Leases for office places are negotiated for terms ranging mainly from one to three years. As at June 30, 2026, the Group had lease liabilities of RMB6.2 million recognized under IFRS 16.

9. Significant investments, material acquisitions and disposals

As at June 30, 2026, we did not hold any significant investments. For the six months ended June 30, 2026, we did not have material acquisitions or disposals of subsidiaries, associates, and joint ventures.

10. Charge on the Group's assets

As at June 30, 2026, none of the Group's assets were charged with any parties or financial institutions (as at December 31, 2025: nil).

11. Foreign exchange exposure

We are exposed to foreign exchange risk arising from certain currency exposures. Our reporting currency is RMB, but a significant portion of our operating transactions, assets, and liabilities are denominated in other currencies such as USD and are exposed to foreign currency risk. We currently do not have a foreign currency hedging policy. However, the management monitors foreign exchange exposure and will consider hedging significant foreign currency exposure should the need arise.

As at June 30, 2026, the Group's restricted bank deposits, time deposits with original maturity over three months and bank balances and cash were denominated as to 52.7% in US dollars, 30.8% in Hong Kong dollars, 16.3% in RMB and 0.2% in Australian Dollars.

12. Employees and remuneration

As at June 30, 2026, we had a total of 80 employees. The following table sets forth the total number of employees by function as of June 30, 2026:

Function	Number of employees	% of total
Research and development	59	74%
Administration	21	26%
Total	80	100%

We enter into individual employment contracts with our employees to cover matters such as wages, benefits, equity incentive, and grounds for termination. We generally formulate our employees' remuneration package to include salary, bonus, equity incentive and allowance elements. Our compensation programs are designed to remunerate our employees based on their performance, measured against specified objective criteria. We also provide our employees with welfare benefits in accordance with applicable regulations and our internal policies.

The Group also has adopted share incentive schemes for the purpose of providing incentives and rewards to its employees.

In accordance with applicable regulations in the PRC, we participate in a pension contribution plan, a medical insurance plan, an unemployment insurance plan, and a personal injury insurance plan for our employees. We have made adequate provisions in accordance with applicable regulations. Additionally, in accordance with PRC regulations, we make annual contributions toward a housing fund, a supplemental medical insurance fund, and a maternity fund.

We provide formal and comprehensive company-level and department-level training to our new employees followed by on-the-job training. We also provide training and development programs to our employees from time to time to ensure their awareness and compliance with our various policies and procedures. Some of the training is conducted jointly by different groups and departments serving different functions but working with or supporting each other in our day-to-day operations.

The total remuneration cost incurred by the Group for the six months ended June 30, 2026 was RMB62.5 million, representing a decrease of RMB21.2 million, as compared to RMB83.7 million for the six months ended June 30, 2025.

13. Treasury policy

Majority of our cash arises from equity funding. Such cash can only be invested in relatively liquid and low-risk instruments such as bank deposits or money market instruments. The primary objective of our investments is to generate finance income at a yield comparable to the interest rate of current bank deposits, with an emphasis on preserving principal and maintaining liquidity.

14. Future plans for material investments or capital assets

Save as disclosed in this report, as of the date of this report, the Group has no specific plan for material investments or acquisition of capital assets.

USE OF NET PROCEEDS FROM THE GLOBAL OFFERING

On July 13, 2021, the Company was successfully listed on the Stock Exchange. The net proceeds received by the Group from the Global Offering (including the partial exercise of the over-allotment option) amounted to approximately HK$2.614 billion (after deducting underwriting fee and relevant expenses).

Details of the planned applications of the net proceeds from the Global Offering were disclosed in the Prospectus and subsequently revised and disclosed in the annual results announcements of the Company dated March 24, 2023, March 21, 2025 and March 19, 2026. The table below sets out the planned applications of the net proceeds and the actual usage up to June 30, 2026:

Use of proceeds	Percentage of total Net Proceeds	Allocation of Net Proceeds (HK$ million)	Unutilized amount as at December 31, 2025 (HK$ million)	Utilized amount during the Reporting Period (HK$ million)	Utilized amount up to June 30, 2026 (HK$ million)	Unutilized amount as at June 30, 2026 (HK$ million)
1. Used for our HBV functional cure programs	56%	1,466.6	648.2	31.3	849.7	616.9
To fund ongoing and planned clinical trials and preparation for regulatory filings for developing combination regimens containing BRII-179, BRII-835 or BRII-877	46%	1,195.9	377.5	31.3	849.7	346.2
Used for IP payments for BRII-179	5%	140.0	140.0	–	–	140.0
Used for the launch and commercialization of HBV curative treatment regimens	5%	130.7	130.7	–	–	130.7
2. Used for our HIV programs, funding the ongoing and planned non-clinical studies, clinical trials and preparation for registration filings for BRII-732 and BRII-753	6%	151.7	–	–	151.7	–
3. Used for our MDR/XDR gram-negative infections programs	3%	67.5	–	–	67.5	–
To fund the ongoing and planned clinical trials and preparation for registration filings for BRII-636, BRII-672 and BRII-693	2%	59.0	–	–	59.0	–
Used for regulatory milestone payments for BRII-636, BRII-672 and BRII-693	0%	8.5	–	–	8.5	–
4. Used for our CNS programs, funding the ongoing and planned non-clinical studies, clinical trials and preparation for registration filings for BRII-296, BRII-297 and other pre-clinical/clinical candidates	11%	274.6	–	–	274.6	–
5. Used for discovery and business development activities for pipeline expansion	15%	392.0	246.9	82.4	227.5	164.5
6. Used for working capital and general corporate purposes	10%	261.4	–	–	261.4	–
Total	100%	2,613.8	895.1	113.7	1,832.4	781.4

For the Company's planned usage of the proceeds as described above, the Company expects that the net proceeds will be used up by the end of 2027.

The unutilized net proceeds will be applied in a manner consistent with the above planned applications and remains subject to change based on the current and future development of market conditions and our actual business needs.

CORPORATE GOVERNANCE AND OTHER INFORMATION

CORPORATE GOVERNANCE PRACTICES

The Group is committed to maintaining high standards of corporate governance to safeguard the interests of the Shareholders and to enhance corporate value and accountability.

The Company has adopted the CG Code as set out in Appendix C1 to the Listing Rules as its own code of corporate governance. During the Reporting Period, the Company has complied with all the applicable code provisions of the CG Code, save and except for the following deviation from code provision C.2.1 of the CG Code.

Under code provision C.2.1 of the CG Code, the roles of chairman and chief executive should be separate and should not be performed by the same individual. Accordingly, the appointment of Dr. Zhi Hong as the chairman of the Board and the chief executive officer of the Company deviates from the relevant code provision. Dr. Zhi Hong, as the founder of the Group, has extensive experience in the biopharmaceutical industry and has served in the Company since its establishment. Dr. Zhi Hong is in charge of overall management, business, strategic development and scientific research and development of the Group. The Board considers that vesting the roles of the chairman of the Board and the chief executive officer of the Company in the same person, Dr. Zhi Hong, is beneficial to the management of the Group. The Board also believes that the combined role of the chairman of the Board and the chief executive officer of the Company can promote the effective execution of strategic initiatives and facilitate the flow of information between management and the Board.

The balance of power and authority is ensured by the operation of the Board, which comprises experienced and diverse individuals. The Board currently comprises two executive Directors and five independent non-executive Directors, and therefore has a strong independent element in its composition. The Board will continue to review the effectiveness of the corporate governance structure of the Group in order to assess whether separation of the roles of chairman and the chief executive officer is necessary.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted its own code of conduct regarding securities transactions of the Directors (the "**Company's Code**") on terms no less exacting than the required standard set out in the Model Code as set out in Appendix C3 to the Listing Rules. Having made specific enquiry with the Directors, all Directors confirmed that they have complied with the required standard as set out in the Model Code and the Company's Code during the Reporting Period. No incident of non-compliance with the Model Code or the Company's Code by the relevant employees who are likely to be in possession of unpublished inside information of the Company was noted by the Company.

INTERIM DIVIDEND

The Board did not declare an interim dividend for the six months ended June 30, 2026 (six months ended June 30, 2025: nil).

AUDIT AND RISK COMMITTEE

The Board has established the Audit and Risk Committee which currently comprises three independent non-executive Directors, namely Ms. Grace Hui Tang, Dr. Taiyin Yang and Mr. Yiu Wa Alec Tsui. Each of Ms. Grace Hui Tang and Dr. Taiyin Yang serves as the co-chairlady of the Audit and Risk Committee, who has the professional qualification and experience in financial matters in compliance with the requirements of the Listing Rules. The primary duties of the Audit and Risk Committee are to review and supervise the Company's financial reporting process, risk management and internal controls.

The Audit and Risk Committee, together with the management and external auditor of the Company, has reviewed the accounting principles and policies adopted by the Company and discussed risk management, internal control system and financial reporting matters of the Group (including the review of the unaudited condensed consolidated financial statements of the Group for the six months ended June 30, 2026), and is of the view that the interim results of the Group for the six months ended June 30, 2026 are prepared in accordance with applicable accounting standards, rules and regulations and appropriate disclosures have been duly made.

CHANGES TO DIRECTORS' INFORMATION

During the Reporting Period and up to the date of this report, the changes in Directors' information, which are required to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules, are set out below:

Name of Director	Details of Change
Ms. Grace Hui Tang (independent non-executive Director)	Ms. Grace Hui Tang has ceased to be an independent director and the chairperson of the remuneration committee of Pirelli & C. S.p.A, a company listed on the Milan Stock Exchange in Italy (stock code: PIRC), upon the constitution of its new board on June 25, 2026, and has ceased to be a director and a member of the audit committee and the operation committee of Elkem ASA, a company listed on the Oslo Stock Exchange in Norway (stock code: ELK), upon the constitution of its new board on July 9, 2026.

CORPORATE GOVERNANCE AND OTHER INFORMATION

PURCHASE, SALE OR REDEMPTION OF LISTED SECURITIES

During the Reporting Period, neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities, including sales of treasury shares (as defined in the Listing Rules). As at June 30, 2026, the Company held a total of 12,723,500 treasury shares (as defined in the Listing Rules).

DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2026, the interests and short positions of the Directors and chief executives of the Company in the shares, underlying shares and debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they were taken or deemed to have under such provisions of the SFO), or which were required, pursuant to section 352 of the SFO, to be entered in the register referred to therein, or which were required to be notified to the Company and the Stock Exchange pursuant to the Model Code, are as follows:

Name of Director/Chief Executive	Capacity/Nature of Interest	Number of Shares/ underlying Shares	Approximate Percentage of Shareholding in the Company[(1)]	Long position/ Short position/ Lending pool
Zhi Hong[(2)]	Trustee	17,212,750	2.34%	Long position
	Founder of discretionary trust	16,000,000	2.18%	Long position
	Beneficial owner	10,382,053	1.41%	Long position
Ankang Li[(3)]	Beneficial owner	8,385,000	1.14%	Long position
Martin J Murphy Jr[(4)]	Beneficial owner	87,000	0.01%	Long position
Grace Hui Tang[(5)]	Beneficial owner	87,000	0.01%	Long position
Yiu Wa Alec Tsui[(6)]	Beneficial owner	87,000	0.01%	Long position
Gregg Huber Alton[(7)]	Beneficial owner	87,000	0.01%	Long position
Taiyin Yang[(8)]	Beneficial owner	327,000	0.04%	Long position

Notes:

1. The calculation is based on the total number of 734,577,057 Shares in issue (including treasury shares (as defined in the Listing Rules)) as of June 30, 2026.

2. Dr. Zhi Hong is interested or deemed to be interested in an aggregate of 43,594,803 Shares, including (i) 564,803 Shares directly held by him; (ii) his entitlements to receive up to 8,305,500 Shares pursuant to the exercise of options granted to him under the 2023 Share Option Scheme, subject to the vesting conditions; (iii) 1,511,750 Shares underlying the RSUs granted to him under the Post-IPO Share Award Scheme and the 2023 Share Award Scheme, subject to the vesting conditions; (iv) 17,212,750 Shares held by an administrative family trust under the JINGFAN HUANG 2020 Revocable Trust, aka JINGFAN HUANG FAMILY TRUST UA DTD 9/24/2020, and the Zhi Hong 2020 Revocable Trust, of which he is the trustee; and (v) 16,000,000 Shares held by the Hong Family 2020 Irrevocable Trust, of which he is the grantor.

3. Dr. Ankang Li is interested in an aggregate of 8,385,000 Shares, including (i) 1,746,957 Shares directly held by him; (ii) his entitlements to receive up to 3,066,668 Shares pursuant to the exercise of options granted to him under the Pre-IPO Share Incentive Plan, subject to the vesting conditions; (iii) his entitlements to receive up to 2,712,500 Shares pursuant to the exercise of options granted to him under the Post-IPO Share Option Scheme and the 2023 Share Option Scheme, subject to the vesting conditions; and (iv) 858,875 Shares underlying the RSUs granted to him under the Post-IPO Share Award Scheme and the 2023 Share Award Scheme, subject to the vesting conditions.

4. Dr. Martin J Murphy Jr directly held 87,000 Shares.

5. Ms. Grace Hui Tang directly held 87,000 Shares.

6. Mr. Yiu Wa Alec Tsui directly held 87,000 Shares.

7. Mr. Gregg Huber Alton directly held 87,000 Shares.

8. Dr. Taiyin Yang directly held 327,000 Shares.

Save as disclosed above, as at June 30, 2026, to the best knowledge of the Directors, none of the Directors or chief executives of the Company had or was deemed to have any interests or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning of Part XV of the SFO) which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which they were taken or deemed to have under such provisions of the SFO), or which were required to be recorded in the register to be kept by the Company pursuant to section 352 of the SFO, or which were required, pursuant to the Model Code, to be notified to the Company and the Stock Exchange.

SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

As at June 30, 2026, so far as the Directors are aware, the following persons (other than the Directors or chief executive of the Company) had interests or short positions in the Shares or underlying Shares of the Company which would be required to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which were required to be recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO:

Name of Shareholder	Capacity/Nature of Interest	Number of Shares	Approximate Percentage of Shareholding in the Company[1]	Long position/ Short position/ Lending pool
ARCH Venture Fund IX, L.P.[2]	Beneficial interest	45,205,210	6.15%	Long position
ARCH Venture Fund IX Overage, L.P.[2]	Beneficial interest	45,205,208	6.15%	Long position
ARCH Venture Partners IX, L.P.[2]	Interest of controlled corporation	45,205,210	6.15%	Long position
ARCH Venture Partners IX Overage, L.P.[2]	Interest of controlled corporation	45,205,208	6.15%	Long position
ARCH Venture Partners IX, LLC[2]	Interest of controlled corporation	90,410,418	12.31%	Long position
Robert Taylor Nelsen[2]	Interest of controlled corporation	90,410,418	12.31%	Long position
Clinton Bybee[2]	Interest of controlled corporation	90,410,418	12.31%	Long position
Keith Crandell[2]	Interest of controlled corporation	90,410,418	12.31%	Long position

Notes:

1. The calculation is based on the total number of 734,577,057 Shares in issue (including treasury shares (as defined in the Listing Rules)) as of June 30, 2026.

2. ARCH Venture Fund IX, L.P. directly held 45,205,210 Shares. The general partner of ARCH Venture Fund IX, L.P. is ARCH Venture Partners IX, L.P., the general partner of which is ARCH Venture Partners IX, LLC. ARCH Venture Partners IX, LLC is owned by several individuals, but its voting power is controlled as to one-third by each of Mr. Robert Taylor Nelsen, Mr. Clinton Bybee and Mr. Keith Crandell. In addition, ARCH Venture Fund IX Overage, L.P. directly held 45,205,208 Shares. The general partner of ARCH Venture Fund IX Overage, L.P. is ARCH Venture Partners IX Overage, L.P., the general partner of which is ARCH Venture Partners IX, LLC.

   For the purpose of the SFO, each of ARCH Venture Partners IX, LLC, Mr. Robert Taylor Nelsen, Mr. Clinton Bybee and Mr. Keith Crandell is deemed to be interested in the Shares held by ARCH Venture Fund IX, L.P. and ARCH Venture Fund IX Overage, L.P. in aggregate.

Save as disclosed above, as at June 30, 2026, the Directors are not aware of any other persons (other than the Directors or chief executive of the Company) who had any interests or short positions in the Shares or underlying Shares of the Company which were required to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which were required to be recorded in the register required to be kept by the Company pursuant to section 336 of the SFO.

SHARE SCHEMES

Pre-IPO Share Incentive Plan

The Pre-IPO Share Incentive Plan was approved and adopted by the Shareholders on October 30, 2018 and subsequently amended on August 27, 2020 and February 26, 2021. The Pre-IPO Share Incentive Plan shall be valid and effective for a period of 10 years from the date of adoption of the plan on October 30, 2018. For details of the principal terms of the Pre-IPO Share Incentive Plan, please refer to Appendix IV to the Prospectus.

Purpose

The purpose of the Pre-IPO Share Incentive Plan is to promote the success of the Company and the interests of its Shareholders by providing a means through which the Company may grant equity-based incentives to attract, motivate, retain and reward certain officers, employees, directors and other eligible persons and to further link the interests of award recipients with those of the Company's shareholders generally. Further details of the Pre-IPO Share Incentive Plan are set out in the Prospectus and note 17 to the consolidated financial statements.

Eligible Participants

Those eligible to participate in the Pre-IPO Share Incentive Plan include officers, directors, employees, advisers or consultants of the Company or any of its affiliates as determined, authorized and approved by the Board or one or more committees appointed by the Board (the "**Administrator**").

Maximum Number of Shares Available for Issue

The overall limit on the number of underlying Shares which may be delivered pursuant to awards granted under the Pre-IPO Share Incentive Plan is 35,816,502 Shares, representing approximately 4.96% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. The total number of Shares available for issue under the Pre-IPO Share Incentive Plan was 5,257,468 Shares, representing approximately 0.73% of the issued Shares (excluding treasury shares (as defined in the Listing Rules)) as at the date of this report.

Under the Pre-IPO Share Incentive Plan, there is no specific limit on the maximum number of Shares which may be granted to a single eligible participant, except that no option may be granted to any person who, at the time the option is granted, owns outstanding shares of the Company (or any of its affiliates) possessing more than 10% of the total combined voting power of all classes of shares of the Company (or any of its affiliates).

Consideration

Nil consideration is required to be paid by the grantees for the grant of awards under the Pre-IPO Share Incentive Plan. There is no specific exercise period of the options granted under the Pre-IPO Share Incentive Plan, which shall be exercisable when they become vested, but each option shall expire not more than 10 years after the date of grant. The Pre-IPO Share Incentive Plan does not require a minimum period for which an award must be held or a performance target which must be achieved before an award can be vested. The Administrator will determine the vesting and/or exercisability provisions of each award (which may be based on performance criteria, passage of time or other factors or any combination thereof), which will be set forth in the applicable award agreement.

Unless the Administrator otherwise expressly provides, once exercisable, an award will remain exercisable until the expiration or earlier termination of the award.

Determination of Exercise Price

The exercise price of an option may be a fixed price based on the par value of an ordinary share of the Company or variable price related to the fair market value of an ordinary share of the Company. The exercise price of all the options and share awards granted under the Pre-IPO Share Incentive Plan is between US$0.035 and US$1.33.

Life of the Pre-IPO Share Incentive Plan

The Pre-IPO Share Incentive Plan commenced on October 30, 2018 (the "**Effective Date**") and will terminate at the close of business on the day before the 10th anniversary of the Effective Date. After the termination of the Pre-IPO Share Incentive Plan either upon such stated expiration date or its earlier termination by the Board, no additional awards may be granted under the Pre-IPO Share Incentive Plan, but previously granted awards (and the authority of the Administrator with respect thereto, including the authority to amend such awards) shall remain outstanding in accordance with their applicable terms and conditions and the terms and conditions of the Pre-IPO Share Incentive Plan. The remaining life of the Pre-IPO Share Incentive Plan is approximately 2.3 years.

Outstanding Share Options

The table below shows details of the outstanding share options granted to all grantees under the Pre-IPO Share Incentive Plan as of June 30, 2026. No options were granted since the Listing Date and up to June 30, 2026. For further details on the movement of the options during the Reporting Period, please see note 17 to the consolidated financial statements.

In connection with the listing of the Shares on the Stock Exchange on the Listing Date, the Board has approved that upon listing, the Company will not grant any additional share options or share awards under the Pre-IPO Share Incentive Plan, so the total number of share options or share awards available for grant under the scheme mandate of the Pre-IPO Share Incentive Plan as at January 1, 2026 and June 30, 2026 is nil and nil, respectively.

As at June 30, 2026, pursuant to the Pre-IPO Share Incentive Plan, the Company had granted to directors, employees and service providers of the Group outstanding options to subscribe for 5,551,968 Shares, representing approximately 0.77% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. There are no participants with options granted in excess of the 1% individual limit for the purpose of Rule 17.03D of the Listing Rules, no service providers (as defined in Chapter 17 of the Listing Rules) with options granted in any 12-month period exceeding 0.1% of the Shares in issue (excluding treasury shares (as defined in the Listing Rules)) for the time being, and no grants to related entity participant (as defined in Chapter 17 of the Listing Rules).

Details of the movements of the options granted under the Pre-IPO Share Incentive Plan during the Reporting Period are as follows:

Name or category of grantee	Exercise price	Date of grant	Vesting commencement date	Number of options						Notes
				Outstanding as at January 1, 2026	Granted during the Reporting Period	Exercised during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding as at June 30, 2026	
1. Director										
Dr. Ankang Li	US$0.13	September 18, 2020	August 31, 2021	1,866,668	–	–	–	–	1,866,668	1
Executive Director	US$0.13	September 18, 2020	July 13, 2022	1,200,000	–	–	–	–	1,200,000	2
2. Other employee participants										
Other employees (in aggregate)	From US$0.035 to US$1.33	From October 30, 2018 to June 4, 2021	From July 1, 2018 to June 7, 2022	2,546,185	–	(144,000)[5]	–	(492,500)	1,909,685	1
3. Service providers										
Service providers (in aggregate)	From US$0.035 to US$1.33	From October 30, 2018 to May 14, 2021	From July 1, 2018 to May 14, 2022	575,615	–	–	–	–	575,615	3, 4
Total:				6,188,468	–	144,000	–	492,500	**5,551,968**	

Notes:

1. In accordance with a vesting schedule, 25% of the options granted on the relevant date of grant will be vested on the vesting commencement date, and the remaining 75% of the options granted on the relevant date of grant will be vested in 36 substantially equal monthly installments with the first installment vesting on the last day of the month following the month in which the vesting commencement date occurs. The options shall be exercisable upon vesting and the exercise period commences on the date when they are vested and ends on the expiry of 10 years from the date of grant.

2. In accordance with a vesting schedule and subject to the satisfaction of certain IPO vesting conditions as specified in the relevant award agreement, 25% of the options granted on the relevant date of grant will be vested on the first anniversary of the completion of the IPO, and 75% of the options granted on the relevant date of grant will be vested in a series of 36 successive equal monthly installments for each monthly period of the relevant grantee's continuous full-time employment with the Company thereafter. The options shall be exercisable upon vesting and the exercise period commences on the date when they are vested and ends on the expiry of 10 years from the date of grant.

3. In accordance with a vesting schedule, the options granted on the relevant date of grant will be vested in 24 substantially equal monthly installments with the first installment vesting on the vesting commencement date occurs. The options shall be exercisable upon vesting and the exercise period commences on the date when they are vested and ends on the expiry of 10 years from the date of grant.

4. In accordance with a vesting schedule, 100% of the options granted on the relevant date of grant will be vested on the vesting commencement date. The options shall be exercisable upon vesting and the exercise period commences on the date when they are vested and ends on the expiry of 10 years from the date of grant.

5. The weighted average closing price of the Shares immediately before the dates on which the options were exercised during the Reporting Period was HK$1.50.

6. The exercise price of the exercised options is between US$0.05 and US$0.13.

7. Closing price of the Shares immediately before the date on which the options were granted is not applicable as the Shares of the Company were not listed at the date of grant.

Post-IPO Share Option Scheme

The Post-IPO Share Option Scheme was approved by the Shareholders on June 22, 2021. The Post-IPO Share Option Scheme shall be valid and effective for a period of 10 years commencing on the Listing Date, subject to early termination in accordance with the terms of the Post-IPO Share Option Scheme. For details of the principal terms of the Post-IPO Share Option Scheme, please refer to Appendix IV to the Prospectus. In view of the amendments to the Listing Rules relating to share schemes which took effect on January 1, 2023 (the "**Share Scheme Amendments**"), the termination of the Post-IPO Share Option Scheme and the adoption of the 2023 Share Option Scheme as proposed by the Company were approved by the Shareholders on September 1, 2023. Following the termination of the Post-IPO Share Option Scheme, no further options have been and will be offered or granted under the Post-IPO Share Option Scheme, but the provisions of the Post-IPO Share Option Scheme shall remain in full force to the extent necessary to give effect to the exercise of any options (to the extent not already exercised) granted prior thereto or otherwise as may be required in accordance with the provisions of the Post-IPO Share Option Scheme.

Purpose

The purpose of the Post-IPO Share Option Scheme is to enable the Group to grant options to selected participants as incentives or rewards for their contribution to the Group. Further details of the Post-IPO Share Option Scheme are set out in the Prospectus and note 17 to the consolidated financial statements.

Eligible Participants

Any directors (including executive directors, non-executive directors and independent non-executive directors), employees, advisors, consultants, distributors, contractors, customers, suppliers, agents, business partners, joint venture business partners or service providers of any member of the Group who the Board considers, in its sole discretion, have contributed or will contribute to the Group.

Maximum Number of Shares Available for Issue

The total number of Shares which may be issued upon exercise of all options to be granted under the Post-IPO Share Option Scheme and any other share option scheme(s) of the Group shall not in aggregate exceed 10% of the Shares in issue on the Listing Date, such 10% limit represents 70,620,092 Shares, representing approximately 9.78% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. Following the termination of the Post-IPO Share Option Scheme, no further option has been and will be offered or granted under the Post-IPO Share Option Scheme.

Maximum Entitlement of Each Participant

Unless approved by Shareholders in a general meeting, the total number of Shares issued and which may fall to be issued upon exercise of the options granted under the Post-IPO Share Option Scheme and any other share option scheme of the Company (including both exercised and outstanding options) to each participant in any 12-month period shall not exceed 1% of the Shares in issue (excluding treasury shares (as defined in the Listing Rules)) for the time being.

Exercise of Option

An option may be exercised in accordance with the terms of the Post-IPO Share Option Scheme at any time during a period to be determined and notified by the Directors to each grantee, which period may commence on a day after the date upon which the offer for the grant of options is made but shall end in any event not later than 10 years from the date of grant of the option subject to the provisions for early termination under the Post-IPO Share Option Scheme. Unless otherwise determined by the Directors and stated in the offer of the grant of options to a grantee, there is no minimum period required under the Post-IPO Share Option Scheme for the holding of an option before it can be exercised, and a grantee is not required to achieve any performance targets before any options granted under the Post-IPO Share Option Scheme can be exercised.

Exercise Price

Pursuant to the Post-IPO Share Option Scheme, the participants may subscribe for the Shares on the exercise of an option granted under the Post-IPO Share Option Scheme at a price determined by the Board provided that it shall not be less than the highest of (a) the closing price of the Shares as stated in the Stock Exchange's daily quotations sheet on the date of grant, which must be a business day; (b) the average closing price of the Shares as stated in the Stock Exchange's daily quotations for the five business days immediately preceding the date of grant; and (c) the nominal value of a Share on the date of grant.

Consideration

A nominal consideration of HK$1.00 must be paid upon acceptance of the grant of an option, and such payment must be made within 5 business days from the date the share option grant offer is made to the grantee.

As at June 30, 2026, pursuant to the Post-IPO Share Option Scheme, the Company had granted to directors and employees of the Group outstanding options to subscribe for 9,658,125 Shares, representing approximately 1.34% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. There are no participants with options granted and to be granted in excess of the 1% individual limit for the purpose of Rule 17.03D of the Listing Rules and no grants to related entity participant (as defined in Chapter 17 of the Listing Rules) or service provider (as defined in Chapter 17 of the Listing Rules). Following the termination of the Post-IPO Share Option Scheme, no further options has been and will be offered or granted under the Post-IPO Share Option Scheme.

Details of the movements of the options granted under the Post-IPO Share Option Scheme during the Reporting Period are as follows:

Name or category of grantee	Date of grant	Exercise price	Number of options: Outstanding as at January 1, 2026	Number of options: Granted during the Reporting Period	Number of options: Exercised during the Reporting Period	Number of options: Cancelled during the Reporting Period	Number of options: Lapsed during the Reporting Period	Number of options: Outstanding as at June 30, 2026	Closing price of the Shares immediately before the date of grant	Notes
1. Director										
Dr. Ankang Li	September 21, 2022	HK$6.454	1,065,000	–	–	–	–	1,065,000	HK$5.91	3,5
Executive Director	August 23, 2023	HK$3.01	545,000	–	–	–	–	545,000	HK$2.77	3
2. Other employee participants										
Other employees (in aggregate)	September 17, 2021	HK$47.6	52,500	–	–	–	–	52,500	HK$48.5	2,3,4
	December 3, 2021	HK$43.41	81,500	–	–	–	–	81,500	HK$40.8	3
	March 29, 2022	HK$10.33	416,500	–	–	–	–	416,500	HK$9.15	3,4,5
	June 24, 2022	HK$9.16	177,750	–	–	–	(177,750)	–	HK$8.57	3
	September 21, 2022	HK$6.454	4,603,875	–	–	–	(674,125)	3,929,750	HK$5.91	3,5
	December 15, 2022	HK$8.64	264,500	–	–	–	(264,500)	–	HK$8.33	3
	April 12, 2023	HK$4.54	762,750	–	–	–	(222,875)	539,875	HK$4.48	3
	June 30, 2023	HK$3.35	801,500	–	–	–	–	801,500	HK$3.13	3
	August 23, 2023	HK$3.01	2,627,250	–	–	–	(400,750)	2,226,500	HK$2.77	3
Total:			11,398,125	–	–	–	(1,740,000)	9,658,125		

Notes:

1. The options granted shall be exercisable upon vesting in accordance with the relevant vesting schedule and the exercise period of the options granted commences on the date on which they are vested in accordance with the relevant vesting schedule and ends on the expiry of 10 years from the relevant date of grant.

2. For the options granted on the date of grant, the options shall be vested over three years from the employment commencement date of each grantee or the date of grant subject to the fulfilment of certain performance targets relating to the Company determined by the Board which are specified in the relevant grant letter of the grantees.

3. For the options granted on the date of grant, the options shall be vested in four tranches as follows: 25% shall vest on the first anniversary of the Vesting Start Date of each grantee; 25% shall vest on the second anniversary of the Vesting Start Date of each grantee; 25% shall vest on the third anniversary of the Vesting Start Date of each grantee; and 25% shall vest on the fourth anniversary of the Vesting Start Date of each grantee, where the "Vesting Start Date" refers to the employment commencement date of each grantee, or the promotion date of each grantee, or the date of grant.

4. For the options granted on the date of grant, the options shall be vested in four tranches as follows: 5% shall vest on the first anniversary of the date of grant; 10% shall vest on the second anniversary of the date of grant; 40% shall vest on the third anniversary of the date of grant; and 45% shall vest on the fourth anniversary of the date of grant.

5. For the options granted on the date of grant, the options shall be vested over three years from the employment commencement date of each grantee upon the achievements by the Group of certain program milestones and/or market capitalization milestones determined by the Board which are specified in the relevant grant letter of the grantees.

Post-IPO Share Award Scheme

The Post-IPO Share Award Scheme was approved by the Shareholders on June 22, 2021. The Post-IPO Share Award Scheme shall be valid and effective for a period of 10 years commencing on the Listing Date, subject to early termination in accordance with the terms of the Post-IPO Share Award Scheme. For details of the principal terms of the Post-IPO Share Award Scheme, please refer to Appendix IV to the Prospectus. In view of the Share Scheme Amendments, the termination of the Post-IPO Share Award Scheme and the adoption of the 2023 Share Award Scheme as proposed by the Company were approved by the Shareholders on September 1, 2023. Following the termination of the Post-IPO Share Award Scheme, no further share awards will be offered or granted under the Post-IPO Share Award Scheme, but the provisions of the Post-IPO Share Award Scheme shall remain in full force to the extent necessary to give effect to the settlement of any share awards granted prior thereto or otherwise as may be required in accordance with the provisions of the Post-IPO Share Award Scheme.

Purpose

The purpose of the Post-IPO Share Award Scheme is to provide participants with the opportunity to acquire proprietary interests in the Company and to encourage participants to work towards enhancing the value of the Company and its Shares for the benefit of the Company and its Shareholders as a whole. Further details of the Post-IPO Share Award Scheme are set out in the Prospectus and note 17 to the consolidated financial statements.

Eligible Participants

Any directors (including executive directors, non-executive directors and independent non-executive directors), employees, advisors, consultants, distributors, contractors, customers, suppliers, agents, business partners, joint venture business partners or service providers of any member of the Group who the Board considers, in its sole discretion, have contributed or will contribute to the Group.

Share Awards

A share award may be granted in the form of Restricted Shares or RSUs under the Post-IPO Share Award Scheme. Restricted Shares are Shares awarded to the participant under the Post-IPO Share Award Scheme. RSU is a non-voting unit of measurement which is deemed for bookkeeping purposes to be equivalent to one Share, such unit to be used solely for the determination of the payment to eventually be made to the participant upon vesting of the applicable award.

Maximum Number of Shares Available for Issue

Shares which may be issued pursuant to all share awards to be granted under the Post-IPO Share Award Scheme must not in aggregate exceed 5% of the Shares in issue on the Listing Date, such 5% limit represents 35,310,046 Shares, representing approximately 4.89% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. Following the termination of the Post-IPO Share Award Scheme, no further RSU has been and will be offered or granted under the Post-IPO Share Award Scheme.

Maximum Entitlement of each Participant

There is no restriction on the maximum entitlement of each participant under the Post-IPO Share Award Scheme. Under the Post-IPO Share Award Scheme, there is no specific limit on the maximum number of share award which may be granted to a single eligible participant, but the maximum share award entitlement of each participant of the Post-IPO Share Award Scheme shall not exceed the limits as required under the Listing Rules.

Grant of Share Award

On and subject to the terms of the Post-IPO Share Award Scheme, the Board shall be entitled (but shall not be bound) at any time within the life of the Post-IPO Share Award Scheme to make an offer of a share award to participant, as the Board may in its absolute discretion select. The Post-IPO Share Award Scheme does not require a minimum period for which a share award must be held or a performance target which must be achieved before a share award can be vested. Share awards may be granted on such terms and conditions as the Board shall determine. Such terms may include any minimum period(s) for which the grantee must be employed or in service to the Group and/or any minimum performance target(s) that must be achieved, before the share award shall vest in whole or in part, and may include at the discretion of the Board such other terms either on a case by case basis or generally.

Acceptance of Share Award

An offer of the grant of a share award shall be deemed to have been accepted and the share award to which the offer relates shall be deemed to have been granted and to have taken effect when the duplicate of the offer letter comprising acceptance of the offer duly signed by the grantee with the number of Shares in respect of which the offer is accepted clearly stated therein. No such offer shall be open for acceptance after the expiry of the period of 10 years commencing on the Listing Date or after the Post-IPO Share Award Scheme has been terminated in accordance with the provisions thereof, whichever is the earlier. In addition, acceptance of an award of Restricted Shares under the Post-IPO Share Award Scheme shall be subject to payment of such consideration to the Company as the Board may determine or as required by applicable law. There is no requirement on the purchase price payable in respect of the share award granted under the Post-IPO Share Award Scheme.

As at June 30, 2026, pursuant to the Post-IPO Share Award Scheme, the Company had granted to directors and employees of the Group outstanding RSUs representing 1,406,250 Shares, accounting for approximately 0.19% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. There are no participants with share awards granted and to be granted in excess of the 1% individual limit for the purpose of Rule 17.03D of the Listing Rules and no grants to related entity participant (as defined in Chapter 17 of the Listing Rules) or service provider (as defined in Chapter 17 of the Listing Rules). Following the termination of the Post-IPO Share Award Scheme, no further share awards will be offered or granted under the Post-IPO Share Award Scheme. The total number of awards available for grant under the scheme mandate of the Post-IPO Share Award Scheme as at January 1, 2026 and June 30, 2026 is nil and nil, respectively.

Details of the movements of the RSUs granted under the Post-IPO Share Award Scheme during the Reporting Period are as follows:

		Number of RSUs							
Name or category of grantee	Date of grant	Outstanding as at January 1, 2026	Granted during the Reporting Period	Vested during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding as at June 30, 2026	Closing price of the Shares immediately before the date of grant	Notes
1. Directors									
Dr. Zhi Hong	September 21, 2022	85,000	–	–	–	–	85,000	HK$5.91	2,5,6
Chairman, chief executive officer and executive Director	August 23, 2023	181,750	–	–	–	–	181,750	HK$2.77	2,5,6
Dr. Ankang Li	September 21, 2022	285,375	–	–	–	–	285,375	HK$5.91	2,6
Executive Director	August 23, 2023	72,250	–	–	–	–	72,250	HK$2.77	2,5,6
2. Other employee participants									
Other employees (in aggregate)	March 29, 2022	126,550	–	(106,405)[7]	(20,145)	–	–	HK$9.15	2,3,4,6
	June 24, 2022	13,125	–	(13,125)[8]	–	–	–	HK$8.57	2,6
	September 21, 2022	403,500	–	–	–	(5,125)	398,375	HK$5.91	2,4,6
	December 15, 2022	26,125	–	–	–	(17,500)	8,625	HK$8.33	2,6
	April 12, 2023	74,000	–	(30,028)[9]	(6,847)	(4,750)	32,375	HK$4.48	2,6
	June 30, 2023	106,500	–	(40,559)[10]	(12,691)	–	53,250	HK$3.13	2,6
	August 23, 2023	310,500	–	–	–	(21,250)	289,250	HK$2.77	2,6
Total:		1,684,675	–	(190,117)	(39,683)	(48,625)	**1,406,250**		

Notes:

1. All the RSUs were granted to the grantees at nil consideration. Once the RSUs are vested in accordance with the relevant vesting schedule, the underlying Shares will be transferred to the grantees at nil consideration.

2. For the RSUs granted on the date of grant, the RSUs shall be vested in four tranches as follows: 25% shall vest on the first anniversary of the Vesting Start Date of each grantee; 25% shall vest on the second anniversary of the Vesting Start Date of each grantee; 25% shall vest on the third anniversary of the Vesting Start Date of each grantee; and 25% shall vest on the fourth anniversary of the Vesting Start Date of each grantee, where the "Vesting Start Date" refers to the employment commencement date of each grantee, or the promotion date of each grantee, or the date of grant.

3. For the RSUs granted on the date of grant, the RSUs shall be vested in four tranches as follows: 5% shall vest on the first anniversary of the date of grant; 10% shall vest on the second anniversary of the date of grant; 40% shall vest on the third anniversary of the date of grant; and 45% shall vest on the fourth anniversary of the date of grant.

4. For the RSUs granted on the date of grant, the RSUs shall be vested over three years from the employment commencement date of each grantee upon the achievements by the Group of certain program milestones and/or market capitalization milestones determined by the Board which are specified in the relevant award agreement of the grantees.

5. The RSUs granted would be satisfied by way of purchase of existing Shares on the secondary market using the Company's internal resources.

6. During the Reporting Period, the purchase price of the vested RSUs or the cancelled RSUs is nil.

7. The weighted average closing price of the Shares immediately before the dates on which the RSUs were vested during the Reporting Period is HK$1.47.

8. The closing price of the Shares immediately before the date on which the RSUs were vested during the Reporting Period is HK$1.10.

9. The weighted average closing price of the Shares immediately before the dates on which the RSUs were vested during the Reporting Period is HK$1.44.

10. The weighted average closing price of the Shares immediately before the dates on which the RSUs were vested during the Reporting Period is HK$1.21.

2023 Share Option Scheme

The adoption of the 2023 Share Option Scheme was approved by the Shareholders on September 1, 2023. The 2023 Share Option Scheme shall be valid and effective for a period of 10 years commencing on the adoption of the scheme on September 1, 2023. The remaining life of the 2023 Share Option Scheme is approximately 7.2 years. For details of the principal terms of the 2023 Share Option Scheme, please refer to the circular of the Company dated August 4, 2023.

Purpose

The purpose of the 2023 Share Option Scheme is to attract and retain eligible participants whose contributions are important to the long-term growth and success of the Group, to recognize and reward eligible participants for their past contribution to the Group, to provide eligible participants with the opportunity to acquire proprietary interests in the Company and to encourage eligible participants to further contribute to the Company and work towards enhancing the value of the Company and its Shares for the benefit of the Company and its Shareholders as a whole.

Eligible Participants

Any director (including executive directors, non-executive directors and independent non-executive directors) and employee of the Company or any of its subsidiaries, and any person who provides services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interests of the long term growth of the Group, who the Board considers, in its sole discretion, have contributed or will contribute to the Group.

Scheme Mandate Limit and Service Provider Sublimit

To the extent permissible under the Listing Rules, the Company may use treasury shares (as defined in the Listing Rules) to satisfy the options granted under the 2023 Share Option Scheme. Any reference to new Shares in the 2023 Share Option Scheme shall also include treasury shares (as defined in the Listing Rules), and references to issuance of Shares shall include the transfer of treasury shares (as defined in the Listing Rules).

The scheme mandate limit is the total number of Shares which may be issued or transferred in respect of all options and awards involving issue of new Shares that may be granted under the 2023 Share Option Scheme, the 2023 Share Award Scheme and any other share scheme(s) of the Company, and shall not in aggregate exceed 10% of the total number of issued Shares (excluding treasury shares (as defined in the Listing Rules)) as at the adoption date of the above schemes (i.e. 72,813,078 Shares). The service provider sublimit, being a sublimit under the scheme mandate limit, is the total number of Shares which may be issued or transferred in respect of all options and awards involving issue of new Shares that may be granted under the 2023 Share Option Scheme, the 2023 Share Award Scheme and any other share scheme(s) of the Company to the service providers, and shall not in aggregate exceed 1% of the total number of issued Shares (excluding treasury shares (as defined in the Listing Rules)) as at the adoption date of the above schemes (i.e. 7,281,307 Shares). The total number of Shares available for issue under the 2023 Share Option Scheme (including the options granted but not yet exercised and the options available for future grants) was 68,069,078 Shares, representing approximately 9.43% of the issued Shares (excluding treasury shares (as defined in the Listing Rules)) as at the date of this report.

Maximum Entitlement of Each Participant

Unless approved by the Shareholders, the total number of Shares issued and to be issued (and/or transferred and to be transferred) in respect of all options and awards granted under the 2023 Share Option Scheme and any other share scheme(s) of the Company to each participant in any 12-month period shall not exceed 1% of the total number of Shares in issue (excluding treasury shares (as defined in the Listing Rules)).

Exercise of Option

Pursuant to the 2023 Share Option Scheme, the Board shall be entitled at any time within the life of the 2023 Share Option Scheme to make an offer of the grant of an option to any eligible participant, as the Board may in its absolute discretion select, to take up an option pursuant to which such participant may subscribe for such number of Shares as the Board may determine at the exercise price and on and subject to such terms and conditions as the Board may determine and impose and inform the grantee accordingly.

The offer shall specify the terms and conditions on which the option is to be granted. Such terms and conditions may include any minimum period(s) for which an option must be held and/or any minimum performance target(s) that must be achieved, before the option can be exercised or vested in whole or in part, may include any clawback mechanism in respect of the option, and may include at the discretion of the Board such other terms either on a case by case basis or generally.

The period within which an option may be exercised is to be determined and notified by the Board to each grantee at the time of making an offer of the grant of an option, which shall not expire later than ten years from the date of grant. Save for the circumstance as described in the 2023 Share Option Scheme, the vesting period in respect of any option granted shall be no less than 12 months from (and including) the date of grant. Subject to the said limitation in relation to vesting period, the 2023 Share Option Scheme does not provide for any minimum period for which an option must be held before it can be exercised or vested.

Consideration

A nominal consideration of HK$1.00 must be paid upon acceptance of the grant of an option, and such payment must be made within five business days from the date the offer of the grant of an option is made to the grantee.

Exercise Price

Pursuant to the 2023 Share Option Scheme, the exercise price in respect of any option shall be such price determined by the Board in its absolute discretion and notified to the participant in the offer of the grant of an option and shall be no less than the higher of: (a) the closing price of the Shares as stated in the daily quotations sheet issued by the Stock Exchange on the date of grant; (b) the average closing price of the Shares as stated in the daily quotations sheets issued by the Stock Exchange for the five business days immediately preceding the date of grant; and (c) the nominal value of a Share on the date of grant.

Upon exercise of the option and payment of the exercise price by the relevant grantee, the Board shall allot and issue new Shares (or transfer treasury shares (as defined in the Listing Rules)) to the grantee.

As at June 30, 2026, pursuant to the 2023 Share Option Scheme, the Company had granted to directors and employees of the Group outstanding options to subscribe for 24,541,375 Shares, representing approximately 3.4% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. There are no participants with options granted and to be granted in excess of the 1% individual limit for the purpose of Rule 17.03D of the Listing Rules and no grants to related entity participant (as defined in Chapter 17 of the Listing Rules) or service provider (as defined in Chapter 17 of the Listing Rules). The total number of options available for grant under the scheme mandate of the 2023 Share Option Scheme as at January 1, 2026 and June 30, 2026 is 41,983,953 and 43,487,203, respectively, and the total number of options available for grant under the service provider sublimit of the 2023 Share Option Scheme as at January 1, 2026 and June 30, 2026 is 6,681,307 and 6,681,307, respectively.

Details of the movements of the options granted under the 2023 Share Option Scheme during the Reporting Period are as follows:

			Number of options								
Name or category of grantee	Date of grant	Exercise price	Outstanding as at January 1, 2026	Granted during the Reporting Period	Exercised during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding as at June 30, 2026	Closing price of the Shares immediately before the date of grant	Fair value of options as at the date of grant[4]	Notes
1. Directors											
Dr. Zhi Hong	October 25, 2024	HK$1.062	6,928,000	–	–	–	–	6,928,000	HK$1.06	HK$0.630	2
Chairman, chief executive officer and executive Director	October 28, 2025	HK$1.832	1,377,500	–	–	–	–	1,377,500	HK$1.85	HK$1.081	3
Dr. Ankang Li	October 25, 2024	HK$1.062	386,500	–	–	–	–	386,500	HK$1.06	HK$0.630	2
Executive Director	October 28, 2025	HK$1.832	716,000	–	–	–	–	716,000	HK$1.85	HK$1.081	3
2. Other employee participants											
Other employees (in aggregate)	March 28, 2024	HK$0.964	4,172,875	–	(65,000)[6]	–	(131,625)	3,976,250	HK$0.93	HK$0.489-HK$0.536	2
	October 25, 2024	HK$1.062	4,787,500	–	(175,250)[7]	–	(318,125)	4,294,125	HK$1.06	HK$0.578-HK$0.589	2
	October 28, 2025	HK$1.832	7,308,250	–	–	–	(1,045,250)	6,263,000	HK$1.85	HK$0.992-HK$1.081	3
3. Service providers											
Service providers (in aggregate)	October 31, 2025	HK$1.82	600,000	–	–	–	–	600,000	HK$1.85	HK$1.079	4
Total:			26,276,625	–	(240,250)	–	(1,495,000)	**24,541,375**			

Notes:

1. The options granted shall be exercisable upon vesting in accordance with the relevant vesting schedule and the exercise period of the options granted commences on the date on which they are vested in accordance with the relevant vesting schedule and ends on the expiry of 10 years from the relevant date of grant.

2. For the options granted on the date of grant, the options shall be vested in four tranches as follows: 25% shall vest on the first anniversary of the Vesting Start Date of each grantee; 25% shall vest on the second anniversary of the Vesting Start Date of each grantee; 25% shall vest on the third anniversary of the Vesting Start Date of each grantee; and 25% shall vest on the fourth anniversary of the Vesting Start Date of each grantee, where the "Vesting Start Date" refers to the employment commencement date of each grantee, or the promotion date of each grantee, or the date of grant.

3. For the options granted on the date of grant, the options shall be vested in four tranches as follows: 25% shall vest on the first anniversary of the Vesting Start Date of each grantee; 25% shall vest on the second anniversary of the Vesting Start Date of each grantee; 25% shall vest on the third anniversary of the Vesting Start Date of each grantee; and 25% shall vest on the fourth anniversary of the Vesting Start Date of each grantee, where the "Vesting Start Date" refers to the last day of the calendar quarter of employment commencement of each grantee, or the promotion date of each grantee, or the date of grant.

4. For the options granted on the date of grant, the options shall be vested in two tranches as follows: 50% shall vest on the first anniversary of the date of grant; and 50% shall vest on the second anniversary of the date of grant.

5. None of the above options granted under the 2023 Share Option Scheme was subject to any performance target.

6. The weighted average closing price of the Shares immediately before the dates on which the options were exercised during the Reporting Period is HK$1.52.

7. The weighted average closing price of the Shares immediately before the dates on which the options were exercised during the Reporting Period is HK$1.49.

2023 Share Award Scheme

The adoption of the 2023 Share Award Scheme was approved by the Shareholders on September 1, 2023. The 2023 Share Award Scheme shall be valid and effective for a period of 10 years commencing on the adoption of the scheme on September 1, 2023. The remaining life of the 2023 Share Award Scheme is approximately 7.2 years. For details of the principal terms of the 2023 Share Award Scheme, please refer to the circular of the Company dated August 4, 2023.

Purpose

The purpose of the 2023 Share Award Scheme is to attract and retain eligible participants whose contributions are important to the long-term growth and success of the Group, to recognize and reward eligible participants for their past contribution to the Group, to provide eligible participants with the opportunity to acquire proprietary interests in the Company and to encourage eligible participants to further contribute to the Company and work towards enhancing the value of the Company and its Shares for the benefit of the Company and its Shareholders as a whole.

Eligible Participants

Any director (including executive directors, non-executive directors and independent non-executive directors) and employee of the Company or any of its subsidiaries, and any person who provides services to the Group on a continuing and recurring basis in the ordinary course of business of the Group which are in the interests of the long term growth of the Group, who the Board considers, in its sole discretion, have contributed or will contribute to the Group.

Scheme Mandate Limit and Service Provider Sublimit

To the extent permissible under the Listing Rules, the Company may use treasury shares (as defined in the Listing Rules) to satisfy the share awards granted under the 2023 Share Award Scheme in place of allotting and issuing new Shares to the grantee. Any reference to new Shares in the 2023 Share Award Scheme shall also include treasury shares (as defined in the Listing Rules), and references to issuance of Shares shall include the transfer of treasury shares (as defined in the Listing Rules).

The scheme mandate limit is the total number of Shares which may be issued or transferred in respect of all options and awards involving issue of new Shares that may be granted under the 2023 Share Option Scheme, the 2023 Share Award Scheme and any other share scheme(s) of the Company, and shall not in aggregate exceed 10% of the total number of issued Shares (excluding treasury shares (as defined in the Listing Rules)) as at the adoption date of the above schemes (i.e. 72,813,078 Shares). The service provider sublimit, being a sublimit under the scheme mandate limit, is the total number of Shares which may be issued or transferred in respect of all options and awards involving issue of new Shares that may be granted under the 2023 Share Option Scheme, the 2023 Share Award Scheme and any other share scheme(s) of the Company to the service providers, and shall not in aggregate exceed 1% of the total number of issued Shares (excluding treasury shares (as defined in the Listing Rules)) as at the adoption date of the above schemes (i.e. 7,281,307 Shares). The total number of Shares available for issue under the 2023 Share Award Scheme (including the share awards granted but unvested and the share awards available for future grants) was 47,657,828 Shares, representing approximately 6.60% of the issued Shares (excluding treasury shares (as defined in the Listing Rules)) as at the date of this report.

Maximum Entitlement of Each Participant

Unless approved by the Shareholders, the total number of Shares issued and to be issued (and/or transferred and to be transferred) in respect of all options and awards granted under the 2023 Share Award Scheme and any other share scheme(s) of the Company to each participant in any 12-month period shall not exceed 1% of the total number of Shares in issue (excluding treasury shares (as defined in the Listing Rules)).

Share Awards

A share award may be granted in the form of Restricted Shares or RSUs under the 2023 Share Award Scheme. Restricted Shares are Shares awarded to a participant under the 2023 Share Award Scheme. RSU is a restricted share unit conferring the grantee a conditional right upon vesting of the RSU to obtain, as determined by the Board in its absolute discretion, either a Share or an equivalent value in cash.

Pursuant to the 2023 Share Award Scheme, the Board shall be entitled at any time within the life of the 2023 Share Award Scheme to make an offer of the grant of a share award to any eligible participant, as the Board may in its absolute discretion select, and on and subject to such terms and conditions as the Board may determine and impose and inform the grantee accordingly.

The offer shall specify the terms and conditions on which the share award is to be granted. Such terms and conditions may include any minimum period(s) for which a share award must be held, any minimum period(s) for which the grantee must be employed or in service to the Group and/or any minimum performance target(s) that must be achieved, before the share award shall vest in whole or in part, may include any clawback mechanism in respect of the share award, and may include at the discretion of the Board such other terms either on a case by case basis or generally.

Save for the circumstance as described in the 2023 Share Award Scheme, the vesting period in respect of any share award granted shall be no less than 12 months from (and including) the date of grant. Subject to the said limitation in relation to vesting period, the 2023 Share Award Scheme does not provide for any minimum period for which a share award must be held before it can be vested.

Consideration

Subject to otherwise determined by the Board at its sole discretion or as required by applicable law in respect of the consideration (if any) for the acceptance of any particular share award which shall be stated in the offer documentation, the grantee is not required to pay any grant or purchase price or make any other payment to the Company to accept a share award granted.

Purchase Price

Subject to otherwise determined by the Board at its sole discretion or as required by applicable law in respect of the purchase price (if any) of any particular share award which shall be stated in the offer documentation, the grantee is not required to pay any purchase price to the Company to purchase any RSU underlying a share award granted or may only be required to pay a nominal value to purchase any Restricted Shares.

Subject to the terms of the 2023 Share Award Scheme, the Board may decide at its sole and absolute discretion to (i) direct the trustee of the 2023 Share Award Scheme to transfer the number of Restricted Shares or the Shares underlying the RSUs to the grantee which the trustee has acquired by making purchases of existing Shares and to be held pending the vesting of the relevant share award; (ii) procure the Company to allot and issue the number of Restricted Shares or the Shares underlying the RSUs (or transfer treasury shares (as defined in the Listing Rules) in accordance with the 2023 Share Award Scheme) to the grantee (as new Shares under the scheme mandate limit) as fully paid up Shares directly; and/or (iii) pay, or procure the payment of, an amount equivalent to the market value of the Shares underlying the RSUs to the grantee in cash, for the purpose of satisfying the relevant share awards of the grantee upon vesting.

As at June 30, 2026, pursuant to the 2023 Share Award Scheme, the Company had granted to directors and employees of the Group outstanding RSUs representing 3,558,750 Shares, accounting for approximately 0.49% of the total issued share capital (excluding treasury shares (as defined in the Listing Rules)) of the Company as at June 30, 2026. There are no participants with share awards granted and to be granted in excess of the 1% individual limit for the purpose of Rule 17.03D of the Listing Rules and no grants to related entity participant (as defined in Chapter 17 of the Listing Rules) or service provider (as defined in Chapter 17 of the Listing Rules). The total number of awards available for grant under the scheme mandate of the 2023 Share Award Scheme as at January 1, 2026 and June 30, 2026 is 41,983,953 and 43,487,203, respectively, and the total number of awards available for grant under the service provider sublimit of the 2023 Share Award Scheme as at January 1, 2026 and June 30, 2026 is 6,681,307 and 6,681,307, respectively.

Details of the movements of the RSUs granted under the 2023 Share Award Scheme during the Reporting Period are as follows:

		Number of RSUs								
Name or category of grantee	Date of grant	Outstanding as at January 1, 2026	Granted during the Reporting Period	Vested during the Reporting Period	Cancelled during the Reporting Period	Lapsed during the Reporting Period	Outstanding as at June 30, 2026	Closing price of the Shares immediately before the date of grant	Fair value of RSUs as at the date of grant(4)	Notes
1. Directors										
Dr. Zhi Hong	October 25, 2024	525,000	–	–	–	–	525,000	HK$1.06	HK$1.04	2
Chairman, chief executive officer and executive Director	October 28, 2025	720,000	–	–	–	–	720,000	HK$1.85	HK$1.82	3
Dr. Ankang Li	October 25, 2024	173,250	–	–	–	–	173,250	HK$1.06	HK$1.04	2
Executive Director	October 28, 2025	328,000	–	–	–	–	328,000	HK$1.85	HK$1.82	3
2. Other employee participants										
Other employees (in aggregate)	March 28, 2024	545,625	–	(102,128)6	(39,747)	(8,250)	395,500	HK$0.93	HK$0.91	2,5
	October 25, 2024	351,000	–	–	–	–	351,000	HK$1.06	HK$1.04	2
	October 28, 2025	1,066,000	–	–	–	–	1,066,000	HK$1.85	HK$1.82	3
Total:		3,708,875	–	(102,128)	(39,747)	(8,250)	3,558,750			

Notes:

1. All the RSUs were granted to the grantees at nil consideration. Once the RSUs are vested in accordance with the relevant vesting schedule, the underlying Shares will be transferred to the grantees at nil consideration.

2. For the RSUs granted on the date of grant, the RSUs shall be vested in four tranches as follows: 25% shall vest on the first anniversary of the Vesting Start Date of each grantee; 25% shall vest on the second anniversary of the Vesting Start Date of each grantee; 25% shall vest on the third anniversary of the Vesting Start Date of each grantee; and 25% shall vest on the fourth anniversary of the Vesting Start Date of each grantee, where the "Vesting Start Date" refers to the employment commencement date of each grantee, or the promotion date of each grantee, or the date of grant.

3. For the RSUs granted on the date of grant, the RSUs shall be vested in four tranches as follows: 25% shall vest on the first anniversary of the date of grant; 25% shall vest on the second anniversary of the date of grant; 25% shall vest on the third anniversary of the date of grant; and 25% shall vest on the fourth anniversary of the date of grant.

4. None of the above RSUs granted under the 2023 Share Award Scheme was subject to any performance target.

5. During the Reporting Period, the purchase price of the vested RSUs or the cancelled RSUs is nil.

6. The weighted average closing price of the Shares immediately before the dates on which the RSUs were vested during the Reporting Period is HK$1.44.

7. Any unvested Shares held by the trustee of the 2023 Share Award Scheme appointed by the Company, Kastle Limited, will abstain from voting on matters that require Shareholders' approval under the Listing Rules.

Additional Information

The number of Shares that may be issued in respect of options and awards granted under all share schemes of the Company during the Reporting Period (i.e. nil) divided by the weighted average number of the Shares in issue (excluding treasury shares (as defined in the Listing Rules)) for the Reporting Period is zero.

DIRECTORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Save as disclosed in this report, at no time during the Reporting Period was the Company or any of its subsidiaries a party to any arrangement that would enable the Directors to acquire benefits by means of acquisition of shares in, or debentures of, the Company or any other body corporate, and none of the Directors or any of their spouses or children under the age of 18 were granted any right to subscribe for the equity or debt securities of the Company or any other body corporate or had exercised any such right.

CONTINUING DISCLOSURE OBLIGATIONS PURSUANT TO THE LISTING RULES

As of June 30, 2026, the Company does not have any disclosure obligations pursuant to Rules 13.20, 13.21 and 13.22 of the Listing Rules.

REPORT ON REVIEW OF CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Deloitte. 德勤

TO THE BOARD OF DIRECTORS OF BRII BIOSCIENCES LIMITED
(incorporated in the Cayman Islands with limited liability)

INTRODUCTION

We have reviewed the condensed consolidated financial statements of Brii Biosciences Limited (the "Company") and its subsidiaries (collectively referred to as the "**Group**") set out on pages 46 to 68, which comprise the condensed consolidated statement of financial position as of June 30, 2026 and the related condensed consolidated statement of profit or loss and other comprehensive income, condensed consolidated statement of changes in equity and condensed consolidated statement of cash flows for the six-month period then ended, and notes to the condensed consolidated financial statements. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 *Interim Financial Reporting* ("**IAS 34**") issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of these condensed consolidated financial statements in accordance with IAS 34. Our responsibility is to express a conclusion on these condensed consolidated financial statements based on our review, and to report our conclusion solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* ("**ISRE 2410**") issued by the International Auditing and Assurance Standards Board. A review of these condensed consolidated financial statements consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34.

Deloitte Touche Tohmatsu
Certified Public Accountants
Hong Kong
August 21, 2026

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED JUNE 30, 2026

	NOTES	Six months ended June 30, 2026 RMB'000 (unaudited)	2025 RMB'000 (unaudited)
Other income	4	19,521	28,127
Other gains and losses, net	5	30,539	170
Research and development expenses		(98,332)	(117,020)
Administrative expenses		(52,576)	(58,225)
Finance costs	6	(132)	(1,900)
Loss before tax	7	(100,980)	(148,848)
Income tax expense	8	–	–
Loss for the period		(100,980)	(148,848)
Other comprehensive expense:			
Items that will not be reclassified to profit or loss:			
Exchange differences on translation from functional currency to presentation currency		(59,798)	(8,956)
Item that may be reclassified subsequently to profit or loss:			
Exchange differences arising on translation of foreign operations		(4,524)	(60)
Other comprehensive expense for the period		(64,322)	(9,016)
Total comprehensive expense for the period		(165,302)	(157,864)
Loss for the period attributable to:			
Owners of the Company		(100,563)	(148,067)
Non-controlling interests		(417)	(781)
		(100,980)	(148,848)
Total comprehensive expense for the period attributable to:			
Owners of the Company		(164,885)	(157,083)
Non-controlling interests		(417)	(781)
		(165,302)	(157,864)
Loss per share	9		
– Basic and diluted (RMB)		(0.14)	(0.20)

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AT JUNE 30, 2026

	NOTES	At June 30, 2026 RMB'000 (unaudited)	At December 31, 2025 RMB'000 (audited)
Non-current assets			
Plant and equipment	11	11,878	3,827
Right-of-use assets	11	7,422	10,346
Intangible assets	11	288,782	298,021
Financial assets at fair value through profit or loss ("**FVTPL**")	12	30,565	7,430
Deposits and other receivables	13	76,376	77,377
		415,023	397,001
Current assets			
Deposits, prepayments and other receivables	13	13,848	21,533
Restricted bank balances	14	1,476	1,532
Time deposits with original maturity over three months	14	1,266,348	1,332,663
Cash and cash equivalents	14	502,980	606,842
		1,784,652	1,962,570
Current liabilities			
Other payables	15	30,185	27,273
Lease liabilities		3,980	5,041
		34,165	32,314
Net current assets		1,750,487	1,930,256
Total assets less current liabilities		2,165,510	2,327,257

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AT JUNE 30, 2026

	NOTES	At June 30, 2026 RMB'000 (unaudited)	At December 31, 2025 RMB'000 (audited)
Non-current liabilities			
Lease liabilities		2,197	3,888
Net assets		2,163,313	2,323,369
Capital and reserves			
Share capital	16	24	24
Share premium and reserves		2,216,026	2,375,665
Equity attributable to owners of the Company		2,216,050	2,375,689
Non-controlling interests		(52,737)	(52,320)
Total equity		2,163,313	2,323,369

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2026

	Attributable to owners of the Company											
	Share capital RMB'000	Treasury shares RMB'000	Shares held in trust RMB'000	Share premium RMB'000	Investments revaluation reserve RMB'000	Translation reserve RMB'000	Other reserve RMB'000 (Note b)	Share-based payment reserve RMB'000	Accumulated losses RMB'000	Sub-total RMB'000	Non-controlling interests RMB'000	Total equity RMB'000
At January 1, 2025 (audited)	24	–	(1)	9,389,863	(45,182)	389,969	(75,917)	203,402	(7,205,201)	2,656,957	(50,877)	2,606,080
Loss for the period	–	–	–	–	–	–	–	–	(148,067)	(148,067)	(781)	(148,848)
Other comprehensive expense for the period	–	–	–	–	–	(9,016)	–	–	–	(9,016)	–	(9,016)
Total comprehensive expense for the period	–	–	–	–	–	(9,016)	–	–	(148,067)	(157,083)	(781)	(157,864)
Derecognition of investments in equity instrument at fair value through other comprehensive income ("FVTOCI") (note c)	–	–	–	–	45,182	–	–	–	(45,182)	–	–	–
Repurchase of ordinary shares (note a)	–	(16,900)	–	–	–	–	–	–	–	(16,900)	–	(16,900)
Vesting of restricted ordinary shares and restricted share units (note 17)	-*	–	–	2,273	–	–	–	(2,273)	–	–	–	–
Exercising of share options (note 17)	-*	–	–	1,003	–	–	–	(774)	–	229	–	229
Recognition of equity-settled share-based payments (note 17)	–	–	–	–	–	–	–	2,261	–	2,261	–	2,261
At June 30, 2025 (unaudited)	24	(16,900)	(1)	9,393,139	–	380,953	(75,917)	202,616	(7,398,450)	2,485,464	(51,658)	2,433,806
At January 1, 2026 (audited)	24	(16,900)	(2)	9,402,120	–	341,783	(75,917)	197,588	(7,473,007)	2,375,689	(52,320)	2,323,369
Loss for the period	–	–	–	–	–	–	–	–	(100,563)	(100,563)	(417)	(100,980)
Other comprehensive expense for the period	–	–	–	–	–	(64,322)	–	–	–	(64,322)	–	(64,322)
Total comprehensive expense for the period	–	–	–	–	–	(64,322)	–	–	(100,563)	(164,885)	(417)	(165,302)
Vesting of restricted ordinary shares and restricted share units (note 17)	-*	–	–	1,320	–	–	–	(1,320)	–	–	–	–
Exercising of share options (note 17)	-*	–	–	800	–	–	–	(470)	–	330	–	330
Recognition of equity-settled share-based payments (note 17)	–	–	–	–	–	–	–	4,916	–	4,916	–	4,916
At June 30, 2026 (unaudited)	24	(16,900)	(2)	9,404,240	–	277,461	(75,917)	200,714	(7,573,570)	2,216,050	(52,737)	2,163,313

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED JUNE 30, 2026

* Amount less than RMB1,000

Note a: During the six months ended June 30, 2025, the Company repurchased 12,723,500 shares at an aggregate consideration of RMB16,900,000, including transaction costs paid by the Company.

Note b: Other reserve represents adjustment to non-controlling interests of a non-wholly subsidiary to reflect changes in the Company's share of net liabilities of this subsidiary upon capital contribution by the Company.

Note c: VBI Vaccines, Inc. ("VBI") initiated restructuring proceedings and was delisted from the NASDAQ Global Market on August 8, 2024. Following completion of the restructuring in January 2025, all the Group's equity investment in VBI had been redeemed and cancelled without consideration. Consequently, the equity investment in VBI held by the Group, which was previously accounted for as financial asset at FVTOCI with carrying amount of nil as at December 31, 2024, was derecognized, and the corresponding debit balance of investment valuation reserve amounted RMB45,182,000 was transferred to accumulated losses upon completion of the restructuring.

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED JUNE 30, 2026

	Six months ended June 30,	
	2026	2025
	RMB'000	RMB'000
	(unaudited)	(unaudited)
NET CASH USED IN OPERATING ACTIVITIES	(165,488)	(221,376)
INVESTING ACTIVITIES		
Interest received	33,822	31,086
Receipt of return from money market funds	6,159	8,083
Placement of time deposits with original maturity over three months	(1,269,925)	(573,738)
Withdrawal of time deposits with original maturity over three months	1,304,996	1,317,072
Withdrawal of restricted bank balances	–	92,484
Purchase of plant and equipment	(9,593)	(29)
Purchase of intangible assets	–	(125,787)
NET CASH FROM INVESTING ACTIVITIES	65,459	749,171
FINANCING ACTIVITIES		
Proceeds from exercise of share options	330	229
Payments of lease liabilities	(2,752)	(2,659)
Payments on repurchase of ordinary shares	–	(16,900)
Interest paid	(132)	(1,900)
NET CASH USED IN FINANCING ACTIVITIES	(2,554)	(21,230)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(102,583)	506,565
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD	606,842	1,003,365
Effects of foreign exchange rate changes	(1,279)	(2,430)
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	502,980	1,507,500

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED JUNE 30, 2026

1. BASIS OF PREPARATION

Brii Biosciences Limited (the "**Company**") was incorporated in the Cayman Islands as an exempted company with limited liability on December 8, 2017. The Company's shares were listed on the Main Board of The Stock Exchange of Hong Kong Limited on July 13, 2021.

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting* issued by the International Accounting Standards Board ("**IASB**") as well as the applicable disclosure requirements of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The directors of the Company have, at the time of approving the condensed consolidated financial statements, a reasonable expectation that the Group has adequate resources to continue in operational existence for the foreseeable future. Thus they continue to adopt the going concern basis of accounting in preparing the condensed consolidated financial statements.

2. ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values, as appropriate.

Other than additional accounting policies resulting from application of amendments to IFRS Accounting Standards, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended June 30, 2026 are the same as those presented in the Group's annual consolidated financial statements for the year ended December 31, 2025.

Application of amendments to IFRS Accounting Standards

In the current interim period, the Group has applied the following amendments to IFRS Accounting Standards issued by the IASB, for the first time, which are mandatorily effective for the Group's annual period beginning on January 1, 2026 for the preparation of the Group's condensed consolidated financial statements:

Amendments to IFRS 9 and IFRS 7	Amendments to the Classification and Measurement of Financial Instruments
Amendments to IFRS 9 and IFRS 7	Contracts Referencing Nature-dependent Electricity
Amendments to IFRS Accounting Standards	Annual Improvements to IFRS Accounting Standards-Volume 11

The application of the amendments to IFRS Accounting Standards in the current interim period has had no material impact on the Group's financial positions and performance for the current and prior periods and/or on the disclosures set out in these condensed consolidated financial statements.

3. SEGMENT INFORMATION

The Group's chief operating decision maker ("**CODM**") has been identified as the Chief Executive Officer of the Group. For the purpose of resource allocation and performance assessment, the CODM reviews the overall results and financial position of the Group as a whole prepared based on the Group's accounting policies. Accordingly, the Group has only one reportable segment and only entity-wide disclosures are presented.

Geographical information

At June 30, 2026, the Group has total non-current assets (excluding financial assets at FVTPL and certain deposits and other receivables) of RMB382,766,000 (December 31, 2025: RMB381,604,000), among which RMB288,782,000 (December 31, 2025: RMB298,021,000) and RMB93,984,000 (December 31, 2025: RMB83,583,000) are located in the Cayman Islands and the People's Republic of China (the "**PRC**"), respectively.

4. OTHER INCOME

	Six months ended June 30,	
	2026 RMB'000 (unaudited)	2025 RMB'000 (unaudited)
Bank interest income	19,216	27,134
Government grants (Note)	–	697
Others	305	296
	19,521	28,127

Note: Government grants including the incentive and other subsidies from the PRC government which are specifically for operating activities are recognised upon compliance with the attached conditions.

5. OTHER GAINS AND LOSSES, NET

	Six months ended June 30,	
	2026 RMB'000 (unaudited)	2025 RMB'000 (unaudited)
Fair value gain on money market funds	6,159	8,083
Fair value gain (loss) on financial assets at FVTPL	23,686	(2,130)
Net foreign exchange gain (loss)	694	(5,065)
Others	–	(718)
	30,539	170

6. FINANCE COSTS

	Six months ended June 30,	
	2026 RMB'000 (unaudited)	2025 RMB'000 (unaudited)
Interest on note payables	–	1,745
Interest on lease liabilities	132	155
	132	1,900

7. LOSS BEFORE TAX

Loss before tax for the period has been arrived at after charging:

	Six months ended June 30,	
	2026 RMB'000 (unaudited)	2025 RMB'000 (unaudited)
Depreciation of plant and equipment	948	340
Depreciation of right-of-use assets	2,924	2,415

8. INCOME TAX EXPENSE

No provision for income tax expense has been made since the operating subsidiaries of the Company have no assessable profits for both periods.

9. LOSS PER SHARE

The calculation of the basic and diluted loss per share attributable to owners of the Company is based on the following data:

	Six months ended June 30,	
	2026	2025
	(unaudited)	(unaudited)
Loss for the period attributable to owners of the Company for the purpose of basic and diluted loss per share (RMB'000)	**(100,563)**	(148,067)
Weighted average number of ordinary shares for the purpose of basic and diluted loss per share ('000)	**734,400**	723,552

For the six months ended June 30, 2025 and 2026, the weighted average number of ordinary shares for the purpose of basic and diluted loss per share excluded the shares held in trust, treasury shares and unvested restricted share units of the Company, details of which are set out in Note 17.

The computation of diluted loss per share for the six months ended June 30, 2025 and 2026 did not assume the exercise of share options and the vesting of unvested restricted share units since their assumed exercise and vesting would be anti-dilutive.

10. DIVIDENDS

No dividend was paid, declared or proposed during the interim period. The directors of the Company have determined that no dividend will be paid in respect of the interim period.

11. MOVEMENTS IN PLANT AND EQUIPMENT, INTANGIBLE ASSETS AND RIGHT-OF-USE ASSETS

During the current interim period, the Group purchased plant and equipment of RMB8,999,000 (six months ended June 30, 2025: RMB29,000) and had no disposal of plant and equipment (six months ended June 30, 2025: nil).

During the current interim period, the Group had no additions of intangible assets (six months ended June 30, 2025: RMB125,787,000) and had no disposal of intangible assets (six months ended June 30, 2025: nil).

BRII-179 is used in combination regimens with elebsiran, in light of the ongoing arbitration with Vir Biotechnology, Inc. ("**Vir**") for a contractual dispute arising from the Collaboration, Option, and License Agreement (the "**Collaboration Agreement**") and the Sixth Letter Agreement (the "**SLA**") that were entered into with Vir (the "**Arbitration**"), and the unknown nature and timing of the outcome of the Arbitration or any mutual resolution of the claims, the Company considers the future of the elebsiran program to be uncertain. Details of the Arbitration are set forth in the Company's announcements dated April 16, 2026, May 22, 2026 and July 3, 2026. During the current interim period, an impairment review of the relevant intangible assets in relation to BRII-179, with carrying amount of RMB152,564,000, has been conducted and no impairment was considered necessary.

11. MOVEMENTS IN PLANT AND EQUIPMENT, INTANGIBLE ASSETS AND RIGHT-OF-USE ASSETS (Continued)

During the six months ended June 30, 2026 and June 30, 2025, the Group had no additions of right-of-use assets and had no termination of lease arrangements.

12. FINANCIAL ASSETS AT FVTPL

At June 30, 2026 and December 31, 2025, financial assets at FVTPL represents investment in an entity listed on the NASDAQ Global Market focusing on infectious diseases. During the six months ended June 30, 2026 and June 30, 2025, the Group has no additions or disposal of the equity investment. The fair value of the listed equity investment is measured based on quoted market price.

13. DEPOSITS, PREPAYMENTS AND OTHER RECEIVABLES

	At June 30, 2026 RMB'000 (unaudited)	At December 31, 2025 RMB'000 (audited)
Prepayments	5,622	4,528
Rental and other deposits	1,712	1,926
Value-added tax recoverable	73,766	69,413
Interests receivable	1,487	16,180
Deposits paid for acquisition of plant and equipment	919	–
Other receivables	6,718	6,863
	90,224	98,910
Less: impairment loss allowance for other receivables	–	–
	90,224	98,910
Analysed as:		
Non-current	76,376	77,377
Current	13,848	21,533
	90,224	98,910

14. RESTRICTED BANK BALANCES/TIME DEPOSITS WITH ORIGINAL MATURITY OVER THREE MONTHS/CASH AND CASH EQUIVALENTS

At June 30, 2026, restricted bank balances included bank deposits held by the trust as part of trust fund which are restricted for transactions related to share award scheme and carry fixed rate interest at 0.01% (December 31, 2025: 0.01%) per annum.

At June 30, 2026, time deposits with original maturity over three months from the date of placement carry fixed rate interest ranging from 1.24% to 3.92% (December 31, 2025: from 1.20% to 4.27%) per annum. These time deposits will mature within 12 months.

Cash and cash equivalents comprise cash, short-term bank deposits with an original maturity of three months or less and low volatility net asset value money market funds. At June 30, 2026, the short-term bank deposits and bank balances carry interests at market rates ranging from 0.01% to 3.40% (December 31, 2025: from 0.01% to 3.80%) per annum. At June 30, 2026, the low volatility net asset value money market funds are measured at fair value of RMB341,125,000 (December 31, 2025: RMB379,514,000).

15. OTHER PAYABLES

	At June 30, 2026 RMB'000 (unaudited)	At December 31, 2025 RMB'000 (audited)
Payables for research and development expenses	12,086	9,153
Accrued research and development expenses	3,150	2,633
Payroll payables	6,412	12,896
Payables for professional fee	5,974	53
Other tax payables	874	1,213
Others	1,689	1,325
	30,185	27,273

15. OTHER PAYABLES (Continued)

The average credit period for purchases of goods/services of the Group is normally within 30 days. Ageing analysis of the Group's payables for research and development expenses based on the invoice dates at the end of the reporting period is as follows:

	At June 30, 2026 RMB'000 (unaudited)	At December 31, 2025 RMB'000 (audited)
0-30 days	10,934	9,079
31-60 days	604	–
61-90 days	248	34
Over 90 days	300	40
	12,086	9,153

16. SHARE CAPITAL

	Number of Ordinary shares	Share capital US$
Ordinary shares		
Ordinary shares of US$0.000005 each		
Authorised		
At January 1, 2025 (audited), June 30, 2025 (unaudited), January 1, 2026 (audited) and June 30, 2026 (unaudited)	1,200,000,000	6,000

16. SHARE CAPITAL (Continued)

	Ordinary Shares		Equivalent amount of ordinary shares
	Number of shares	Amount	
		US$	RMB'000
Issued and fully paid			
At January 1, 2025 (audited)	731,309,790	3,657	24
Issuance of ordinary shares in relation to exercise of share options (Note 17)	320,000	2	-*
Issuance of ordinary shares in relation to vesting of restricted share units (Note 17)	428,701	2	-*
At June 30, 2025 (unaudited)	732,058,491	3,661	24
At January 1, 2026 (audited)	733,900,562	3,670	24
Issuance of ordinary shares in relation to exercise of share options (Note 17)	384,250	2	-*
Issuance of ordinary shares in relation to vesting of restricted share units (Note 17)	292,245	1	-*
At June 30, 2026 (unaudited)	734,577,057	3,673	24

* Less than RMB1,000.

Note: During the six months ended June 30, 2025, the Company repurchased 12,723,500 shares of its own ordinary shares through the Stock Exchange of Hong Kong Limited with an aggregate consideration of RMB16,900,000, including transaction costs. They are not cancelled and are recorded as treasury shares at the end of the reporting period.

17. SHARE-BASED PAYMENT TRANSACTIONS

Share option incentive plans

(a) Pre-IPO Share Incentive Plan

The Company's pre-IPO share incentive plan (the "**Pre-IPO Share Incentive Plan**") was adopted pursuant to shareholders' approval on October 30, 2018. The primary purpose of the Pre-IPO Share Incentive Plan is to promote the success of the Company and the interests of its shareholders by providing a mean through which the Company may grant equity-based incentives to attract, motivate, retain and reward employees, directors and consultants (the "**Eligible Persons**") and to further link the Eligible Persons' interests with those of the Company's shareholders generally.

(b) Post-IPO Share Option Scheme

On June 22, 2021, a Post-IPO share option scheme (the "**Post-IPO Share Option Scheme**") was adopted pursuant to shareholders' approval. The purpose of the Post-IPO Share Option Scheme is to enable the Group to grant options to selected participants as incentives or rewards for their contribution to the Group.

In view of the amendments to the Rules Governing the Listing of Securities on the Stock Exchange relating to share schemes which took effect on January 1, 2023, the termination of the Post-IPO Share Option Scheme and the adoption of the 2023 Share Option Scheme (as defined below) as proposed by the Company were approved by the Shareholders on September 1, 2023. Following the termination of the Post-IPO Share Option Scheme, no further options will be offered or granted under the Post-IPO Share Option Scheme, but the provisions of the Post-IPO Share Option Scheme shall remain in full force to the extent necessary to give effect to the exercise of any options (to the extent not already exercised) granted prior thereto or otherwise as may be required in accordance with the provisions of the Post-IPO Share Option Scheme.

(c) 2023 Share Option Scheme

On September 1, 2023, 2023 share option scheme (the "**2023 Share Option Scheme**") was adopted pursuant to shareholders' approval. The primary purpose of the 2023 Share Option Scheme is to attract and retain eligible persons whose contributions are important to the long-term growth and success of the Company, to recognise and reward eligible persons for their past contribution to the Company, to provide eligible persons with the opportunity to acquire proprietary interests in the Company and to encourage eligible persons to further contribute to the Company and work towards enhancing the value of the Company and its shares for the benefit of the Company and its shareholders as a whole.

17. SHARE-BASED PAYMENT TRANSACTIONS (Continued)

Share option incentive plans (Continued)

Set out below are details of the movements of the outstanding options granted under the Pre-IPO Share Incentive Plan, the Post-IPO Share Option Scheme and the 2023 Share Option Scheme during the reporting period:

For the six months ended June 30, 2026

Option	Type of grantee	Date of grant	Vesting period	Exercisable period	Exercise price	Outstanding at 1.1.2026	Granted during the period	Exercised during the period	Forfeited during the period	Outstanding at 30.6.2026
Time-based										
Option A	Consultants and employees	30.10.2018	Note i	Note iii	US$0.035	590,000	–	–	–	590,000
Option B	Consultants and employees	3.4.2019 – 16.9.2019	Note i	Note iii	US$0.05	320,000	–	(40,000)	–	280,000
Option C	Employees	4.2.2020 – 11.12.2020	Note i	Note iii	US$0.13 – US$0.68	3,603,668	–	(104,000)	(314,500)	3,185,168
Option D	Consultants and employees	18.2.2021 – 3.12.2021	Note i	Note iii	US$0.68 – US$1.33 HK$43.41 – HK$47.60	608,800	–	–	(178,000)	430,800
Option E	Employees	29.3.2022 – 15.12.2022	Note i	Note iii	HK$6.454 – HK$10.33	6,271,125	–	–	(1,116,375)	5,154,750
Option I	Employees	12.4.2023 – 23.8.2023	Note i	Note iii	HK$3.01 – HK$4.54	4,736,500	–	–	(623,625)	4,112,875
Option J	Employees	28.3.2024	Note i	Note iii	HK$0.964	4,172,875	–	(65,000)	(131,625)	3,976,250
Option K	Employees	25.10.2024	Note i	Note iii	HK$1.062	12,102,000	–	(175,250)	(318,125)	11,608,625
Option L	Employees	28.10.2025	Note i	Note iii	HK$1.832	9,401,750	–	–	(1,045,250)	8,356,500
Option M	Consultants	31.10.2025	Note i	Note iii	HK$1.82	600,000	–	–	–	600,000
Sub-total						42,406,718	–	(384,250)	(3,727,500)	38,294,968
Milestone-based										
Option F	Employees	18.9.2020	Note ii	Note iii	US$0.13 – US$0.68	1,200,000	–	–	–	1,200,000
Option H	Employees	29.3.2022 – 21.9.2022	Note ii	Note iii	HK$6.454 – HK$10.33	256,500	–	–	–	256,500
Sub-total						1,456,500	–	–	–	1,456,500
Total						43,863,218	–	(384,250)	(3,727,500)	39,751,468
Weighted average exercise price						HK$2.66	–	HK$0.96	HK$4.37	HK$2.55

17. SHARE-BASED PAYMENT TRANSACTIONS (Continued)

Share option incentive plans (Continued)

For the six months ended June 30, 2025

Option	Type of grantee	Date of grant	Vesting period	Exercisable period	Exercise price	Outstanding at 1.1.2025	Granted during the period	Exercised during the period	Forfeited during the period	Outstanding at 30.6.2025
Time-based										
Option A	Consultants and employees	30.10.2018	Note i	Note iii	US$0.035	985,000	–	–	–	985,000
Option B	Consultants and employees	3.4.2019 – 16.9.2019	Note i	Note iii	US$0.05	440,000	–	(120,000)	–	320,000
Option C	Employees	4.2.2020 – 11.12.2020	Note i	Note iii	US$0.13 – US$0.68	3,803,668	–	(200,000)	–	3,603,668
Option D	Consultants and employees	18.2.2021 – 3.12.2021	Note i	Note iii	US$0.68 – US$1.33 HK$43.41 – HK$47.60	749,800	–	–	(101,000)	648,800
Option E	Employees	29.3.2022 – 15.12.2022	Note i	Note iii	HK$6.454 – HK$10.33	9,998,000	–	–	(1,979,250)	8,018,750
Option I	Employees	12.4.2023 – 23.8.2023	Note i	Note iii	HK$3.01 – HK$4.54	6,350,875	–	–	(737,625)	5,613,250
Option J	Employees	28.3.2024	Note i	Note iii	HK$0.964	5,104,500	–	–	(392,000)	4,712,500
Option K	Employees	25.10.2024	Note i	Note iii	HK$1.062	14,073,000	–	–	(588,000)	13,485,000
Sub-total						41,504,843	–	(320,000)	(3,797,875)	37,386,968
Milestone-based										
Option F	Employees	18.9.2020	Note ii	Note iii	US$0.13 – US$0.68	1,200,000	–	–	–	1,200,000
Option H	Employees	29.3.2022 – 21.9.2022	Note ii	Note iii	HK$6.454 – HK$10.33	818,000	–	–	(561,500)	256,500
Sub-total						2,018,000	–	–	(561,500)	1,456,500
Total						43,522,843	–	(320,000)	(4,359,375)	38,843,468
Weighted average exercise price						HK$3.21	–	HK$0.78	HK$5.13	HK$3.01

17. SHARE-BASED PAYMENT TRANSACTIONS (Continued)

Share option incentive plans (Continued)

Notes:

(i) The share options were granted to employees of the Group or consultants who are in contractual agreements with the Group in providing services similar to those rendered by the Group's employees. The vesting is based on the vesting schedules within the vesting period of 1 – 4 years.

(ii) The milestone-based share options are vested conditionally upon the achievement of the specified performance target milestones. The expected vesting period is estimated by the directors of the Company based on the most likely outcome of the performance conditions.

(iii) Each vested option is exercisable during a period from and including the vesting date of the relevant option to the tenth anniversary of grant date of the option.

For the six months ended June 30, 2026, the Group's share-based payment expenses recognised in the condensed consolidated statement of profit or loss and other comprehensive income in relation to share options granted by the Company is RMB3,155,000 (six months ended June 30, 2025: RMB836,000).

Share award schemes

(a) Post-IPO Share Award Scheme

On June 22, 2021, a Post-IPO share award scheme (the "**Post-IPO Share Award Scheme**") was approved by shareholders, pursuit to which the Company may make an offer of a share award (consisting of either restricted share or restricted share unit ("**RSU**")) to an eligible person in accordance with the Post-IPO Share Award Scheme. The maximum number of shares which may be awarded to any eligible person under the Post-IPO Share Award Scheme shall not exceed 5% of the shares in issue upon listing on July 13, 2021, which is 35,310,046 shares.

17. SHARE-BASED PAYMENT TRANSACTIONS (Continued)

Share award schemes (Continued)

(a) Post-IPO Share Award Scheme (Continued)

The following table summarised the movement of RSUs granted under the Group's Post-IPO Share Award Scheme during the reporting period.

	Number of Post-IPO RSUs
At January 1, 2025 (audited)	4,612,375
Granted	–
Vested	(323,223)
Forfeited	(771,502)
At June 30, 2025 (unaudited)	3,517,650
At January 1, 2026 (audited)	1,684,675
Granted	–
Vested	(190,117)
Forfeited	(88,308)
At June 30, 2026 (unaudited)	1,406,250

17. SHARE-BASED PAYMENT TRANSACTIONS (Continued)

Share award schemes (Continued)

(b) 2023 Share Award Scheme

On September 1, 2023, 2023 share award scheme (the "**2023 Share Award Scheme**") was adopted pursuant to shareholders' approval. The 2023 Share Award Scheme shall be valid and effective for a period of 10 years upon adoption. The purpose of the 2023 Share Award Scheme is consistent with the 2023 Share Option Scheme.

The following table summarised the movement of RSUs granted under the Group's 2023 Share Award Scheme during the reporting period.

	Number of RSUs under 2023 Share Award Scheme
At January 1, 2025 (audited)	2,315,750
Granted	–
Vested	(105,478)
Forfeited	(195,147)
At June 30, 2025 (unaudited)	2,015,125
At January 1, 2026 (audited)	3,708,875
Granted	–
Vested	(102,128)
Forfeited	(47,997)
At June 30, 2026 (unaudited)	3,558,750

For the six months ended June 30, 2026, the Group's share-based payment expenses recognised in the condensed consolidated statement of profit or loss and other comprehensive income in relation to RSUs granted by the Company is RMB1,761,000 (six months ended June 30, 2025: RMB1,425,000).

18. CAPITAL COMMITMENTS

	At June 30, 2026 RMB'000 (unaudited)	At December 31, 2025 RMB'000 (audited)
Capital expenditure in respect of acquisition of contracted for leasehold improvement or property and equipment but not provided in the condensed consolidated financial statements	2,534	1,241

19. RELATED PARTY TRANSACTIONS

Compensation of key management personnel

The remuneration of directors of the Company and other members of key management of the Group during the interim period were as follows:

	Six months ended June 30,	
	2026 RMB'000 (unaudited)	2025 RMB'000 (unaudited)
Short term benefits	16,403	16,969
Discretionary bonus (note)	946	5,752
Post-employment benefits	478	613
Share-based payments	3,699	791
	21,526	24,125

Note: Discretionary bonus is determined based on their duties and responsibilities of the relevant individuals within the Group and the Group's performance.

20. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Some of the Group's financial instruments are measured at fair value for financial reporting purposes. The Chief Strategy and Financial Officer of the Company determines the appropriate valuation techniques and inputs for fair value measurements. In estimating the fair value, the Group uses market observable data to the extent it is available.

The fair values of these financial assets are determined (in particular, the valuation technique(s) and inputs used), as well as the level of the fair value hierarchy into which the fair value measurements are categorised (Levels 1 to 3) based on the degree to which the inputs to the fair value measurements is observable.

- Level 1 fair value measurements are based on quoted prices (unadjusted) in active market for identical assets or liabilities that the entity can access at the measurement date;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the asset or liability that are not based on observable market data (unobservable inputs).

(i) Fair value of the Group's financial assets that are measured at fair value on a recurring basis

Financial assets	Notes	Fair value at June 30, 2026 RMB'000 (unaudited)	Fair value at December 31, 2025 RMB'000 (audited)	Fair value hierarchy	Valuation techniques and key inputs	Significant unobservable inputs
Listed equity investment at FVTPL	12	30,565	7,430	Level 1	Active market quoted transaction price	N/A
Money market funds	14	341,125	379,514	Level 2	Based on the net asset value of the funds, which are determined with reference to observable and quoted prices of underlying investment portfolio	N/A

20. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS (Continued)

(ii) Fair value of the financial assets and liabilities that are not measured at fair value

The directors of the Company consider that the carrying amount of the Group's financial assets and financial liabilities recorded at amortised cost in these condensed consolidated financial statements approximate their fair values. Such fair values have been determined in accordance with generally accepted pricing models based on a discounted cash flow analysis.

21. EVENTS AFTER THE REPORTING PERIOD

There was no material event taken place subsequent to the reporting period other than those disclosed in Note 11.

DEFINITIONS

In this report, unless the context otherwise requires, the following expressions shall have the following meanings.

"2023 Share Award Scheme"	the 2023 share award scheme adopted by the Company on September 1, 2023, as amended from time to time
"2023 Share Option Scheme"	the 2023 share option scheme adopted by the Company on September 1, 2023, as amended from time to time
"Audit and Risk Committee"	the audit and risk committee of the Board
"Board"	the board of directors of the Company
"CG Code"	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
"CHD"	chronic hepatitis D
"China" or "the PRC"	the People's Republic of China excluding, for the purposes of this report, Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Company", "we", "us" or "Brii Bio"	Brii Biosciences Limited (騰盛博药生物科技有限公司), an exempted company with limited liability incorporated under the laws of the Cayman Islands, the Shares of which are listed on the Main Board of the Stock Exchange
"Director(s)"	director(s) of the Company
"EASL"	the European Association for the Study of the Liver
"EFdA"	an NRTTI and an investigational drug for the treatment of HIV infection
"ENHANCE study"	a study to evaluate the efficacy and safety of combination therapy of BRII-179, elebsiran and PEG-IFNα in participants with chronic HBV infection
"ENRICH study"	a study to investigate the efficacy and safety of regimens containing BRII-179, elebsiran, and PEG-IFNα treating chronic HBV infection
"ENSURE study"	a study to investigate the efficacy and safety of elebsiran and PEGIFNα combination therapy in chronic HBV patients

DEFINITIONS

"EOT"	end-of-treatment
"Global Offering"	the Hong Kong initial public offering and the international offering of the Company
"Greater China"	mainland China, Hong Kong, the Macau Special Administrative Region of the People's Republic of China and Taiwan
"Group"	the Company and its subsidiaries
"HBsAg"	hepatitis B surface antigen
"HBV"	hepatitis B virus
"HCC"	hepatocellular carcinoma
"HDV"	hepatitis D virus
"HIV"	human immunodeficiency virus
"HK$" or "HKD"	Hong Kong dollars and cents respectively, the lawful currency of Hong Kong
"Hong Kong"	the Hong Kong Special Administrative Region of the People's Republic of China
"IFRS"	International Financial Reporting Standard
"IP"	intellectual property
"Joincare Group"	Joincare Pharmaceutical Group Industry Co., Ltd, a company incorporated in the PRC
"Listing Date"	July 13, 2021, the date on which the Shares were listed on the Stock Exchange and from which dealings in the Shares were permitted to commence on the Stock Exchange
"Listing Rules"	the Rules Governing the Listing of Securities on the Stock Exchange
"MDR/XDR"	multi-drug resistant/extensive drug resistant

“Model Code”	the Model Code for Securities Transactions by Directors of Listed Issuer as set out in Appendix C3 to the Listing Rules
“mRNA”	messenger RNA, a class of single-stranded RNA molecules that carry genetic instructions transcribed from DNA to direct protein synthesis in cells
“NCE”	new chemical entity
“Nomination Committee”	the nomination committee of the Board
“NRTTI”	nucleoside analogue reverse transcriptase translocation inhibitor
“PEG-IFNα”	pegylated interferon alfa
“Post-IPO Share Award Scheme”	the post-IPO share award scheme adopted by the Company on June 22, 2021
“Post-IPO Share Option Scheme”	the post-IPO share option scheme adopted by the Company on June 22, 2021
“Pre-IPO Share Incentive Plan”	the pre-IPO share incentive plan approved and adopted by the Company on October 30, 2018
“Prospectus”	the prospectus of the Company dated June 30, 2021
“Reporting Period”	the six months ended June 30, 2026
“RMB” or “CNY”	Renminbi, the lawful currency of the PRC
“RNA”	ribonucleic acid
“RSU(s)”	restricted stock unit(s)
“R&D”	research and development

DEFINITIONS

"SFO"	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong
"Share Schemes"	collectively, the Pre-IPO Share Incentive Plan, the Post-IPO Share Option Scheme, the Post-IPO Share Award Scheme, the 2023 Share Option Scheme and the 2023 Share Award Scheme
"Share(s)"	ordinary share(s) in the share capital of the Company with a nominal value of US$0.000005 each
"Shareholder(s)"	the holder(s) of the Share(s)
"siRNA"	small interfering RNA, sometimes known as short interfering RNA or silencing RNA, a class of double stranded non-coding RNA molecules
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Strategy Committee"	the strategy committee of the Board
"United States" or "U.S." or "USA"	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
"US$" or "USD"	United States dollars, the lawful currency of the United States
"U.S. FDA"	the U.S. Food and Drug Administration
"Vir Biotechnology"	Vir Biotechnology, Inc., a corporation incorporated in San Francisco, the United States, whose stocks are listed on the NASDAQ Global Market (NASDAQ: VIR)
"%"	per cent.